













































































































Medulloblastoma	 survivors	 frequently	 suffer	 from	 low	 quality	 of	 life	 as	 a	 result	 of	
aggressive	 treatment.	 New	 treatments	 are	 urgently	 needed	 to	 reduce	 down-stream	
sequelae.	GD3,	an	oncofoetal	ganglioside,	has	roles	in	embryonic	brain	development	and	
is	commonly	modified	to	9-O-acetyl	GD3	(GD3A).	GD3A	plays	a	role	in	protecting	cells	from	
pro-apoptotic	 GD3	 during	 brain	 development,	 after	 which	 GD3	 accumulates	 above	 a	
threshold	to	collapse	the	mitochondrial	membrane	potentials	of	supernumary	progenitor	
cells.	GD3	and	GD3A	then	become	minor	ganglioside	species	of	the	postpartum	brain.	In	





(SIAE),	 is	 significantly	down-regulated	 in	medulloblastoma	patient	 tissue	 (p<0.001).	 This	
enzyme	is	thought	to	restore	GD3	levels	by	cleaving	the	acetyl	groups	from	GD3A.	In	order	
to	evaluate	this	pathway	as	a	potential	therapeutic	target	we	used	an	inducible	SIAE	over-
expression	 approach	 in	 RES256	 cells,	 the	 highest	 intracellular	 GD3A	 expresser.	 This	
transfection	resulted	in	two	SIAE	wild-type	expressing	clones.	Upon	over-expression	of	SIAE	
(in	clone	2)	we	show	a	significant	increase	in	GD3	expression	(p<0.05),	and	in	preliminary	
experiments	 a	 significant	 increase	 in	 depolarisation	 of	 the	 mitochondrial	 membrane	
potential	was	seen	in	SIAE	expressing	clone	1	(p<0.05).	These	changes	were	not	seen	on	





in	 cell	 lysates	 were	 confirmed	 by	Western	 blot	 and	 demonstrated	 a	 possible	 cleavage	

































































































































































































TABLE	2.2	CELL	LINES	AND	CULTURE	CONDITIONS	 	 	 	 	 	 												100	
TABLE	2.3	TABLE	OF	THE	ANTIBODIES	USED	THROUGHOUT	THE	PROJECT		 	 	 												106		
TABLE	2.4	COMPONENTS	USED	FOR	LINEARIZATION	OF	PTRE3G-IRES	BACKBONE	VECTOR																												114		
TABLE	2.5	PRIMERS	WITH	INFUSION	CLONING	OVERHANGS	FOR	CLONING	 	 	 												116	
TABLE	2.6	COMPONENTS	OF	PCR	REACTIONS	FOR	AMPLIFICATION	OF	GENES	 	 														 	 116	
TABLE	2.7	THERMAL	CYCLING	CONDITIONS	FOR	CLONING	 	 	 	 																	 116	













































CEREBELLUM																											 	 	 	 	 	 	 																												182	
FIGURE	3.12	HYPOTHESIS	 	 	 	 	 	 	 	 																												184	
FIGURE	3.13	SANGER	SEQUENCING	DEMONSTRATES	THAT	SIAE	AND	SIAE-S127A	GENES	WERE	
SUCCESSFULLY	CLONED	INTO	THE	PTRE3G-IRES-EGFP	PLASMIDS	 	 	 	 												187	
FIGURE	3.14	THE	TET-ON	3G	INDUCIBLE	EXPRESSION	SYSTEM	 	 	 	 	 												189	
FIGURE	3.15	TWO	PROTEINS	ARE	EXPRESSED	FROM	ONE	MRNA	TRANSCRIPT	USING	AN	INTERNAL	















































































































































































































































cases	of	paediatric	brain	 cancer	and	76	 resulting	deaths,	meaning	over	a	 third	of	 these	
patients	 succumbed	 to	 their	 disease	 (35%)	 (Office	 for	 National	 Statistics	 2013).	 These	
statistics	 have	 been	 generated	 from	 data	 obtained	 from	 patients	 under	 the	 age	 of	 15,	




(WHO)	 (Louis	 et	 al.	 2016).	 The	 currently	 recognised	 embryonal	 tumours	 are	
medulloblastoma	 (genetically	 or	 histologically	 defined;	 or	 not	 otherwise	 specified);	
embryonal	 tumour	with	multilayer	 rosettes	 (C19MC-altered	or	not	otherwise	specified);	
CNS	 neuroblastoma;	 CNS	 ganglioneuroblastoma;	 medulloepithelioma;	 atypical	
teratoid/rhabdoid	tumour;	CNS	embryonal	tumour	with	rhabdoid	features;	and	finally,	CNS	

















disease,	 Li-Fraumeni	 syndrome,	Gorlin	 syndrome,	 Turcot	 syndrome,	 Cowden	 syndrome,	
hereditary	 retinoblastoma	 and	 Rubinstein-Taybi	 syndrome	 (American	 Cancer	 Society	
2014).	Some	of	these	syndromes	have	helped	to	understand	some	of	the	underlying	biology	
of	their	associated	tumours,	such	as	Gorlin	syndrome,	in	which	patients	have	mutations	in	

















that	 can	 be	 accompanied	 by	 bulging	 of	 the	 fontanelles	 as	 the	 tumour	 pushes	 outward	
against	 the	 unfused	 bone	 plates	 (American	 Cancer	 Society	 2014).	 This	 diverse	 range	 of	






cerebellum,	 brainstem	 and	 spinal	 cord.	Most	 of	 the	 childhood	 tumours	 occur	 in	 these	
regions	due	 to	 rapid	proliferation	of	 cells	 in	 this	 area	during	development	of	 the	brain,	
including	 the	 granule	 neuron	 precursors	 of	 the	 cerebellum	 which	 can	 give	 rise	 to	
medulloblastoma	when	faults	occur	(Gibson	et	al.	2010).	Medulloblastoma	is	an	embyronal	
cancer	which	most	commonly	arises	from	the	neuronal	precursor	cells.	This	cellular	origin	






cancers,	 such	 as	 leukaemia,	 and	 as	 a	 group	 they	 account	 for	 more	 than	 a	 quarter	 of	







Most	 cases	 of	 this	 disease	 are	 diagnosed	 in	 children	 under	 ten,	 with	 a	 peak	 incidence	
between	 the	 ages	 of	 three	 and	 eight	 (Millard	&	 De	 Braganca	 2015).	 The	WHO	 defines	
medulloblastoma	as	a	grade	IV	disease.	Grade	IV	is	the	highest	grade	of	malignancy	that	
the	WHO	 assigns.	 This	 classification	means	 that	 this	 tumour	 is	 cytologically	 malignant,	
mitotically	active,	prone	to	necrosis	and	is	associated	with	rapid	pre-	and	post-operative	
disease	evolution.	Medulloblastoma	also	meets	grade	 IV	criteria	as	 the	disease	 features	
widespread	 infiltration	 of	 surrounding	 brain	 tissue	 and	 tendency	 for	 cranial-spinal	
dissemination	(World	Health	Organisation	2007).		
Symptoms	 of	 medulloblastoma	 encompass	 the	 general	 symptoms	 of	 brain	 tumours	
described	 in	 section	 1.1.3,	 but	 due	 to	 their	 location	 patients	 also	 show	 symptoms	
associated	with	 cerebellar	 dysfunction	 and	 blockage	 of	 cerebral	 spinal	 fluid	 (CSF)	 flow.	
Symptoms	of	medulloblastoma	include	vomiting,	particularly	in	the	morning.	The	time	of	










Medulloblastoma	 is	 a	 developmental	 tumour	 of	 the	 cerebellum	 so	 named	 by	 Harvey	








&	 De	 Braganca	 2015).	 It	 is	 important	 to	 understand	 how	 these	 oncogenic	 signalling	
pathways	contribute	to	medulloblastoma	as	this	will	help	to	improve	clinical	management	
of	the	disease.	With	these	discoveries	there	will	be	more	accurate	predictors	of	disease	risk	
and	 refinement	 of	 appropriate	 therapeutic	 strategies.	 Pharmacological	 intervention	 of	
these	pathways	will	become	more	targeted	and	could	lead	to	the	development	of	new	and	

























are	 generated,	 the	older	 cells	 begin	 to	differentiate	 and	migrate	 inwards,	 by	 extending	
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when	 the	 EGL	 depletes	 and	 the	 GCPs	 all	 mature	 into	 granule	 neurons	 (Wechsler-Reya	
2003).	 It	 is	 thought	 that	 if	 faults	 arise	 during	 this	 process,	 medulloblastoma	 occurs	
(Wechsler-Reya	&	Scott	2001b).	Medulloblastoma	cells	are	not	completely	 like	any	non-












by	 Taylor	 et	 al.	 (2012).	 These	 molecular	 subgroups	 are	 defined	 by	 genetic	 and	
transcriptional	 signatures,	 which	 include	mutations	 in	 the	WNT	 and	 the	 SHH	 signalling	
pathways.	Generic	names	are	given	to	subgroups	3	and	4	as	there	is	much	less	known	about	
the	underlying	biology	of	 these	subgroups,	 importantly	 the	subgroups	are	also	clinically	
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patterning,	 and	 differentiation	 (Kalderon	 2002).	WNT	 proteins	 are	 a	 family	 of	 secreted	
molecules.	Wnt-1,	the	first	WNT	protein	to	be	identified,	is	known	to	be	required	in	early	
























WNT	 proteins	 bind	 to	 their	 receptors,	 frizzleds	 (FZDs).	 With	 WNT	 protein	 bound,	 the	










Mutations	 in	 APC	 were	 first	 implicated	 in	 medulloblastoma	 pathogenesis	 in	 Turcot	
syndrome	patients	(Hatten	&	Roussel	2011).	Mutations	in	APC	have	only	been	found	in	4%	





residues	 S33	 and	 S37	 (Gilbertson	 2004).	 These	mutations	 prevent	 the	 phosphorylation-
dependent	 degradation	 of	 β-catenin	 by	 GSK3.	 These	 mutations	 cause	 β-catenin	 to	






survival	 rates	 are	 around	 95%	 (Gajjar	&	 Robinson	 2014).	 This	 subgroup	 is	 the	 rarest	 in	
incidence,	accounting	for	10%	of	cases	(Goschzik	et	al.	2015).	Of	these	only	5%	of	cases	
present	with	metastatic	disease	(Gajjar	&	Robinson	2014).	Generally,	patients	who	die	from	
this	 subgroup	 of	 medulloblastoma	 die	 from	 complications	 of	 treatment	 or	 secondary	
neoplasm	rather	than	the	primary	disease	Taylor	et	al.	2012.	Treatment	of	this	subgroup	is	
justifiably	 considered	 too	 aggressive	 given	 the	 high	 survival	 rates.	 Some	 patients	 are	
therefore	 given	 reduced-dose	 craniospinal	 radiotherapy	 and	 reduced	 intensity	
chemotherapy	because	of	 this,	but	 they	must	not	have	metastatic	disease	and	must	be	
enrolled	in	clinical	trial	(Gilbertson	2004).	The	reason	for	better	outcome	for	WNT	patients	





The	 location	 of	 this	 subgroup	 of	 tumour	 is	 distinct,	 it	 occurs	 in	 the	 cerebellar	midline,	










but	does	not	occur	 in	every	patient.	Other	 than	monosomy	6	 there	are	 very	 few	other	
























and	 translocates	 to	 the	 nucleus	 where	 it	 binds	 to	 the	 transcription	 factor	 T-cell	
factor/lymphoid	 enhancer	 factor	 (LEF/TCF)	 and	 initiates	 the	 transcription	 of	 known	
oncogenes	 such	 as	 c-myc	 and	 cyclin	 D1.	 In	Medulloblastoma,	WNT	 signalling	 can	 be	
activated	 without	 WNT	 ligand	 binding	 due	 to	 mutations	 in	 the	 β-catenin	 protein	
sequence	 that	 prevent	 its	 phosphorylation.	 These	 mutations	 mean	 β-catenin	 is	 not	
degraded	as	it	cannot	be	ubiquitinated.	Adapted	from	Gilbertson	2004.		
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Table	 1.1	Disease	 features	 of	WNT	medulloblastoma.	 The	proposed	 cell	 of	 origin	 and	








Candidate	genes	 WNT	 pathway,	 Dickkopf-related	 protein	 1	










PTCH1	 is	 an	 example	 of	 a	 gene	 that	 controls	 cell	 fate	 and	 growth	 in	 the	 developing	
cerebellum	(Tichy	et	al.	2015).	If	PTC1	function	is	reduced,	for	example	by	mutation,	then	
this	growth	can	become	unregulated	and	contribute	to	pathogenesis	of	medulloblastoma	













closely	 related	 to	 the	 frizzled	 family	 of	WNT	 receptors	 (Taipale	 et	 al.	 2002).	 PTC1	may	




that	 includes	 fused	and	 suppressor-of-fused	 (SUFU)	 (Rubin	&	de	Sauvage	2006).	GLI1	 is	
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sequestered	into	this	complex,	preventing	the	activation	of	gene	transcription.	GLI2	and	






and	 SUFU	 (Gilbertson	 2004).	 The	 binding	 of	 SHH	 to	 PTC1	 removes	 the	 suppression	 of	
smoothened	(Taipale	et	al.	2002).	When	smoothened	is	active	the	multi-protein	complex,	
which	 contains	 fused	 and	 suppressor-of-fused,	 is	 disrupted	 (Gilbertson	 2004).	
Subsequently,	GLI1	is	released	and	activates	gene	expression	(Rubin	&	de	Sauvage	2006).	







































































Table	 1.2	 Disease	 features	 of	 SHH	medulloblastoma.	 The	 proposed	 cell	 of	 origin	 and	
developmental	 stage	 are	 thought	 to	 be	 when	 aberrant	 SHH	 signalling	 drives	
tumorigenesis.	Adapted	from	Gajjar	&	Robinson	2014.		
Disease	Feature	 SHH	Subgroup	
























of	 tumour	 very	 frequently	 present	 with	 metastatic	 disease	 (40-45	 %	 cases)	 (Gajjar	 &	
Robinson	2014).	This	subgroup	is	more	common	in	infants	and	children	but	is	almost	never	











outcome	of	 the	WNT	subgroup	 is	 retained	 in	 these	patients	 (Staal	et	al.	2015).	Another	
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suggested	marker	of	this	subgroup	is	 immunohistochemical	positivity	for	atrionatriuretic	
peptide	 receptor	 C	 (NPR3)	 (Taylor	 et	 al.	 2012).	 Despite	 these	 suggestions	 group	 3	 is	





Genetic	 characteristics	 of	 this	 subgroup	 are	 also	 shared	with	 group	 4,	 however	 gain	 of	
chromosome	1q	and/or	loss	of	chromosomes	5q	and	10q	are	much	more	likely	to	be	seen	

































may	 help	 to	 define	 this	 subgroup	 (Taylor	 et	 al.	 2012).	 It	 has	 also	 been	 suggested	 that	
positive	immunohistochemical	staining	of	the	protein	Potassium	Channel,	Voltage	Gated	
Shaker	Related	Subfamily	A,	Member	1	 (KCNA1),	a	potassium	channel,	could	define	this	
subgroup	 (Taylor	 et	 al.	 2012).	 Both	 of	 these	 markers	 requires	 further	 validation	 as	
expression	may	not	 be	 exclusive	 to	 group	4	 tumour	 and	 the	 clinical	 relevance	of	 these	
markers	are	not	yet	apparent	(Taylor	et	al.	2012).	The	most	frequent	mutation	seen	in	this	




however	 this	mutation	 is	more	 commonly	 seen	 in	males	 than	 females	 (Robinson	 et	 al.	
2012).	 In	addition	10%	of	patients	also	have	a	single	copy	gain	of	5q23.2,	where	the	a-
































Table	 1.5	 Summary	 of	 disease	 features	 in	 each	 of	 the	 molecular	 subgroups	 of	

















































































































The	WNT	and	SHH	pathways	are	unlikely	 to	be	 the	only	 cell-signalling	 systems	 that	are	




has	been	associated	with	 favourable	outcome	 in	medulloblastoma	patients	 (Segal	et	al.	
1994).	 Studies	have	also	 identified	platelet-derived	growth	 factor	 receptor	 (PDGFR)	and	
RAS	 MAPK	 pathway	 activation	 as	 potential	 mediators	 for	 dissemination	 of	
medulloblastoma	(Gilbertson	&	Clifford	2003;	MacDonald	et	al.	2001).		
There	is	also	evidence	that	the	aberrant	expression	of	Erb-B2	Receptor	Tyrosine	Kinase	2	
(ERBB2)	 in	 granule-neuron	 precursor	 cells	 of	 the	 cerebellum	 may	 have	 a	 role	 in	
medulloblastoma	 formation	 (Gilbertson	 et	 al.	 1997;	Gilbertson	 et	 al.	 2001;	Gajjar	 et	 al.	








network	 of	 hetero-	 and	 homodimerisations	 (Muthuswamy	 et	 al.	 1999).	 ERBB	 dimers	
activate	the	cell	signalling	pathways	of	mitogen-activated	protein	kinase	(MAPK),	AKT	and	
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signal	 transducer	 and	 activator	 of	 transcription	 (STAT),	 which	 allows	 them	 to	 regulate	
several	key	cell	processes	such	as	proliferation,	apoptosis,	migration	and	differentiation	
(Zomerman	et	al.	2015).			
When	 aberrant	 up-regulation	 of	 ERBB2	 occurs	 cell	 transform	 can	 also	 occur	 (Yarden	&	



















emerge.	 These	 therapeutics	 target	 cell-signalling	 pathways	 that	 function	 abnormally	 in	
medulloblastoma.	
Cyclopamine	 is	 a	 plant-derived	 teratogen	 that	 inhibits	 the	 SHH	pathway	 (Samkari	 et	 al.	
2015).	The	mechanism	of	action	of	this	drug	is	to	bind	to	and	thus	inactivate	smoothened	
(Samkari	 et	 al.	 2015).	 This	 drug	 is	 only	 suitable	 for	 patients	with	 recurrent	 disease	 and	
either	 PTC1	 mutations	 or	 some	 SMO	 mutations,	 leaving	 around	 50%	 of	 SHH	 patients	
predicted	to	respond	(Gilbertson	2004).		Cyclopamine	specifically	targets	the	SHH	pathway	
in	medulloblastoma	cells,	causing	the	inhibition	of	GLI-mediated	gene	expression,	cell	cycle	
arrest	 and	 therefore	 has	 antineoplastic	 activity	 (Gilbertson	 2004;	 Samkari	 et	 al.	 2015).	
Other	smoothened	antagonists	are	in	preclinical	development	and	are	expected	to	enter	
early	clinical	trials	for	medulloblastoma	within	the	next	few	years.	Recently,	resistance	to	
















are	 gemcitabine	 and	pemetrexed,	 these	drugs	have	been	 shown	 to	have	 some	efficacy	
against	 MYC	 amplification	 (Morfouace	 et	 al.	 2014).	 Bromodomain	 and	 extraterminal	
domain	 (BET)	 antagonists,	 which	 interfere	with	MYC-associated	 transcription	 have	 also	
shown	 some	 efficacy	 against	 these	 tumours	 in	 mice	 and	 some	 xenografted	 cell	 lines	
(Bandopadhayay	et	al.	2014;	Henssen	et	al.	2013).		
1.7 Histopathological	variants	









SHH	 Classic,	 desmoplastic/nodular	 (predominantly),	 large	
cell/anaplastic,	MBEN	(nearly	all	MBENs	are	SHH)	

































these	 changes	 however	 are	 particularly	 pronounced	 in	 the	 anaplastic	 variant.	 In	 some	





expanded	 lobular	 architecture.	 Expansion	of	 these	areas	are	due	 to	 reticulin-free	 zones	
which	become	usually	large	and	rich	in	neuropil-like	tissue.	Reticulin-free	zones	contain	a	
population	of	cells	which	resemble	those	of	a	neurocytoma	and	exhibit	a	streaming	pattern.	
























a	 typical	 arrangement	 of	 sheets	 of	 undifferentiated	 cells.	 (B)	 Desmoplastic/nodular	
medulloblastoma	showing	pale	nodular	areas	surrounded	by	densely	packed	hyperchromatic	
cells.	(C)	Large	cell/anaplastic	medulloblastoma	showing	enlarged	vesicular	nuclei,	prominent	
nucleoli	 and	 moderate	 cytoplasm.	 (D)	 Medulloblastoma	 with	 extensive	 nodularity	 has	 a	
lobular	 architecture	 with	 large	 elongated	 reticulin-free	 zones.	 These	 zones	 contain	 small	






Current	 treatment	 for	 medulloblastoma	 includes	 maximal	 safe	 surgical	 resection,	
radiotherapy	if	the	patient	is	over	3	years	of	age,	and	high-dose	chemotherapy	(Schuler	et	
al.	 2014).	 Survivors	 of	 this	 disease	 often	 suffer	 significant	 treatment-related	 sequelae	
including	 endocrine	 disorders	 and	 neurocognitive	 deficits	 (Michiels	 et	 al.	 1996).	 These	
problems	occur	as	the	nature	of	treatment	is	aggressive	and	damaging	to	the	developing	
brain	tissue	(Gajjar	et	al.	1999).		




2004).	One	explanation	 for	 age-dependent	disease	behaviour	 is	 the	 restriction	 that	 age	
imposes	on	treatment.	Children	under	three	do	not	have	radiotherapy	as	it	would	inflict	






operative	MRI	and	 if	 there	 is	presence	of	secondary	 tumours	 (Ramaswamy	et	al.	2015).	
Medulloblastoma	has	the	ability	to	migrate	and	form	secondary	tumour	masses	through	
leptomeningeal	 dissemination	 or	 possibly	 via	 vascular	 metastasis	 (Garzia	 et	 al.	 2015).	
Around	a	 third	of	 	patients	present	with	CNS	dissemination	at	 time	of	diagnosis	 (World	
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Health	Organisation	2007).	A	 small	 but	 important	 group	of	patients	 also	develop	extra-
neural	 metastasis	 to	 the	 bone,	 bone	marrow,	 lymph	 nodes,	 liver	 or	 lung.	 This	 type	 of	
medulloblastoma	is	staged	according	to	Chang’s	criteria	(metastatic	or	M	stage;	table	1.7)	























anaplasia	 on	histological	 examination	 (Borowska	&	 Jóźwiak	 2016).	 Patients	who	do	not	
meet	these	criteria	are	classified	as	high-risk	(Tarbell	et	al.	2013).	In	Europe,	the	patient’s	
age	and	m	stage	(≤M1	vs	≥	M2)	alone	are	used	to	assign	disease	risk	(Gilbertson	2004).	This	








Packer	 et	 al.	 1999;	 Strother	 et	 al.	 2001).	 As	 radiotherapy	 is	 so	 damaging	 to	 the	 non-











still	 in	 its	 recruitment	 stage	 (Children's	 Oncology	 Group	 2013).	 Post-operative	
chemotherapy	 and	 radiation	 are	 also	 used	 to	 treat	 average-risk	 patients	 in	 Europe,	
although	the	neuraxis	dose	has	not	yet	been	reduced	from	35.0	Gy	(Gilbertson	2004).	
There	have	been	several	chemotherapeutic	regimens	that	have	been	investigated	for	the	









than	 50%	 (Ellison	 et	 al.	 2003).	 Some	 combination	 chemotherapy	 and	 radiotherapy	
treatments	have	yielded	more	promising	results.	A	study	by	St.	Jude’s	Children’s	hospital	














One	 such	 approach	 involves	 a	 ganglioside	 acetylation	 pathway	 known	 to	 function	








expressed	 throughout	 the	body	but	 are	most	 abundant	 in	 the	grey	matter	of	 the	brain	





microdomain	 structures	 of	 the	 lipid	 rafts,	 often	with	 signalling	 and	 adhesion	molecules	
(Sorice	et	al.	2012).	In	addition	to	being	localised	on	the	cell	surface,	gangliosides	are	also	





















GM3,	 the	 simplest	 ganglioside,	 is	 generated	 by	 the	 addition	 of	 sialic	 acid	 to	 its	 LacCer	
backbone	by	GM3	synthase	(Proia	2004).		Further	sialic	acid	residues	are	then	added	to	this	
GM3	 structure	 by	 other	 specific	 sialyltransferases,	 for	 example	GD3	 synthase	 (ST8Sia1)	
forming	GD3	(Yu	et	al.	2004).	When	GM3,	GD3	and	GT3	lack	N-acetylgalactosamine,	they	
serve	 as	 precursors	 for	 the	 more	 complex	 gangliosides	 which	 are	 generated	 through	
addition	 of	 sialic	 acids	 through	 more	 promiscuous	 sialyltransferases	 along	 specific	
pathways	(Yu	et	al.	2004).	The	start	of	the	ganglioside	biosynthesis	pathway	is	shown	in	
figure	 1.5.	 The	 expression	 levels	 and	 patterning	 of	 the	 gangliosides	 undergo	 dramatic	
changes	 throughout	 brain	 development	 and	 disease	 states	 such	 as	 cancer	 (Schengrund	
2015).	 For	 example,	 in	 the	 human	 embryonic	 brain,	 the	major	 gangliosides	 are	 simple,	
GM3,	 GD3	 and	 9-O-acetyl	 GD3	 (GD3A)	 (Ryan	 et	 al.	 2013).	 As	 the	 brain	 develops,	 the	
expression	of	 these	simple	gangliosides	 is	 replaced	with	 the	more	complex	gangliosides	
such	 as	 GM1,	 GD1a	 and	 GT1b	 (Yu	 et	 al.	 2012).	 This	 change	 is	 tightly	 regulated	 at	 the	







lactosylceramide	 then	 has	 sialic	 acids	 added	 to	 it	 by	 a	 series	 of	 sialyltransferases	
generating	the	gangliosides.	Biosynthesis	of	the	individual	gangliosides	runs	in	parallel	
pathways	forming	the	a-	b-	and	c-	series	gangliosides.	The	synthesis	of	the	gangliosides	




























in	 intensity	when	the	dendritic	tree	 increases	 in	complexity	(Goldman	&	Reynolds	1996;	
Reynolds	&	Wilkin	1988).	
In	the	developing	cerebellum	the	immature	GD3	positive	granule	neurons	of	the	EGL	retain	
the	 ganglioside	 until	 they	 begin	 to	 migrate	 through	 the	 molecular	 layer	 (Goldman	 &	




GD3	has	 been	 shown	 to	 have	 roles	 in	 differentiation	 and	 neurite	 sprouting	 (Sato	 et	 al.	
2002),	in	a	cell	type	dependent	manner	(Malisan	&	Testi	2002a).	For	example,	in	ST8Sia1	




















over-expression,	 demonstrating	 that	 GD3	 expression	 is	 sufficient	 to	 cause	 apoptosis	
(Malisan	&	Testi	2002a).		
In	other	studies,	the	collapse	of	the	mitochondrial	membrane	potential	is	the	mechanism	
by	 which	 GD3	 leads	 to	 cell	 death	 (Birks	 et	 al.	 2011).	 This	 is	 the	 most	 well-accepted	
mechanism	of	action	for	GD3-mediated	apoptosis	(Malisan	&	Testi	2002a).	The	collapse	of	





lymphoma	2	 (bcl-2)	 (Rippo	et	al.	2000).	When	 the	PTPC	 is	opened,	 there	 is	an	outward	








In	 a	 study	 by	 Colell	 GD3	 was	 shown	 to	 suppress	 the	 activation	 of	 the	 pro-survival	
transcription	 factor	nuclear	 factor	of	kappa	 light	polypeptide	gene	enhancer	 (NF-kB)	by	
preventing	its	nuclear	translocation	(Colell	et	al.	2001).		
Another	 mechanism	 of	 GD3-induced	 cell	 death	 that	 has	 been	 described	 is	 autophagy	
(Garcia-Ruiz	et	al.	2015).	Recent	findings	have	revealed	a	previously	undetermined	role	for	
GD3	 in	 autophagy.	 GD3	 has	 been	 shown	 in	 a	 study	 by	 Matarresse	 to	 regulate	 the	
autophagosome	 formation	 (Matarrese	et	al.	 2014).	Cells	were	amino	acid	deprived	and	
ganglioside	GD3	was	shown	to	contribute	to	the	biogenesis	and	maturation	of	autophagic	
vacuoles.	 Knock	down	 studies	 of	 ST8Sia1	 showed	 impaired	 autophagy	while	 exogenous	
GD3	administration	was	 shown	 to	 resume	autophagy,	providing	 supporting	evidence	of	
GD3’s	 involvement	 in	 this	 process	 (Matarrese	 et	 al.	 2014).	 In	 addition	 to	 these	 effects,	
gangliosides	 have	 been	 shown	 to	 induce	 autophagic	 cell	 death	 in	 astrocytes	 by	 a	























































suggested	 that	 the	 expression	 differences	 may	 reflect	 different	 stages	 of	 maturation.	































how	 tumour	 cells	 evade	 apoptosis	 (Kniep	 et	 al.	 2006).	 One	 of	 the	 reasons	 why	 pre-
treatment	of	cells	may	become	resistant	to	apoptosis	 is	suggested	by	(Chen	et	al.	2006)	
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who	 suggested	 that	 GD3	 can	 include	 its	 own	 acetylation	 machinery.	 This	 group	 used	
exogenously	added	GD3	to	determine	if	the	expression	of	GD3A	increased	with	treatment.	


















that	 tumour	progression	occurs	 in	 a	 ganglioside	dependent	manner	has	been	 shown	 in	
conjunction	 with	 clinicopathological	 studies	 which	 demonstrate	 that	 there	 are	 some	
ganglioside	 species	 with	 relatively	 simple	 structures,	 GD3	 is	 an	 example	 of	 such	 a	
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ganglioside	 (Pukel	 et	 al.	 1982),	 that	 shows	 very	 restricted	 expression	 in	 non-neoplastic	
tissues	 and	markedly	 increased	 expression	 in	 some	malignancies	 (Birklé	 et	 al.	 2003).	 A	
number	 of	 functional	 roles	 for	 gangliosides	 have	 been	 proposed,	 many	 of	 which	 are	
important	 in	 neoplasia	 and	 also	 in	 the	 developing	 and	 non-neoplastic	 nervous	 tissue	
(Pilkington	et	al.	1993).	
The	ganglioside	GD3	 is	 the	most	widely	 studied	 in	neoplastic	disease	as	 it	 is	 commonly	
expressed	 in	 tumour	 tissues	 such	 as	 malignant	 melanoma	 and	 glioma	 (Hersey	 1991;	





has	 been	 studied	 in	 primary	 brain	 tumours	 (Parker	 &	 Pilkington	 2005;	 Koochekpour	 &	
Pilkington	 1996;	 Gratsa	 et	 al.	 1997;	 Birks	 et	 al.	 2011).	 GD3	 has	 many	 known	 roles	 in	
neoplastic	 disease,	 for	 example	 in	 cell	 growth,	 invasion	 and	 evasion	 of	 the	 immune	
response	 (Birklé	 et	 al.	 2003).	 GD3A	 also	 has	 roles	 in	 neoplasia	 and	 has	 been	 shown	 to	
influence	cell	survival	in	several	cancers	such	as	acute	lymphoblastic	leukaemia	(Mukherjee	
et	al.	2008)	and	glioblastoma	multiforme	(Birks	et	al.	2011).		






migration	of	neuronal	progenitor	 cells	 as	well	 as	 causing	 the	apoptosis	of	 supernumary	
progenitors	 (Ogiso	 et	 al.	 1991).	 Expression	 of	 GD3	 is	 tightly	 regulated	 depending	 on	
developmental	stage	and	GD3	 is	also	 involved	 in	cancers	of	development.	GD3	 is	highly	
expressed	by	the	brain	tissue	and	several	studies	have	investigated	expression	in	primary	











neuroblastoma	 by	 the	 use	 of	 anti-GD3	 antibodies	 which	 have	 been	 shown	 to	 reduce	
angiogenesis	in	a	rat	model	(Zeng	et	al.	2000).		
Studies	 have	 shown	 that	 GD3	 is	 involved	 in	 the	 attachment	 of	 human	melanoma	 and	
neuroblastoma	cells	to	various	extracellular	matrix	proteins,	including	laminin,	fibronectin,	
collagen,	 and	 vitronectin	 (Cheresh	 et	 al.	 1986).	 In	 glioma	 it	 has	 been	 shown	 that	
exogenously	added	gangliosides	stimulate	cell	invasion	in	vitro	and	in	addition	this	has	been	
shown	that	gangliosides	enhance	the	adhesion	of	glioma	cell	lines	to	fibronectin,	laminin,	
vitronectin	 and	 collagen	 I	 (Merzak	 et	 al.	 1994;	 Koochekpour	 et	 al.	 1995).	 In	 a	 study	 by	
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Merzak	et	al.	(1995)	invasion	in	glioma	cells	was	found	to	involve	gangliosides	and	this	was	
thought	 to	 be	 mediated	 by	 adhesion-promoting	 action	 to	 the	 basement	 membrane	
proteins	(Merzak	et	al.	1995).	It	was	also	shown	that	secretion	of	matrix	metalloproteinases	
2	and	9	was	affected	by	ganglioside	expression,	but	this	was	not	correlated	with	histological	
















the	 suppression	 of	 the	 anti-tumour	 immune	 response	 is	 supported	 by	 studies	
demonstrating	 that	 tumour	 cells	 synthesise	 and	 shed	 gangliosides	 into	 their	
microenvironments	 (Potapenko	et	al.	2007).	GD3	can	be	actively	shed	 from	the	 tumour	
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cells	 to	 the	 microenvironment	 where	 it	 can	 bind	 and	 interact	 with	 a	 wide	 variety	 of	
proteins,	including	extracellular	matrix	(ECM)	modulating	proteins	such	as	integrins	(Kong	
et	al.	1998;	Dolo	et	al.	2000;	Ohkawa	et	al.	2008).	Shed	GD3	can	also	be	incorporated	into	
the	 membrane	 of	 neighbouring	 cells,	 which	 helps	 to	 modulate	 tumour–host	 cell	
interactions	 (Olshefski	 &	 Ladisch	 1996).	 This	 process	 is	 important	 as	 this	 is	 one	 of	 the	
mechanisms	 by	 which	 evasion	 of	 the	 immune	 response	 is	 thought	 to	 occur	 in	 glioma	









Genetic	 evidence	 suggested	 one	 gene	was	 responsible	 for	 the	 transfer	 of	 acetyl	 group	
(Arming	et	al.	2011;	Campbell	et	al.	1994).	The	human	genome	database	was	screened	for	








found	 in	 proteins	 that	 translocate	 to	 the	 ER,	 Golgi	 or	 plasma	 membrane.	 The	 protein	
consists	of	a	serine-glycine-asparagine-histidine	(SGNH)	hydrolase	domain	and	a	C-terminal	
transmembrane	 domain	 (Arming	 et	 al.	 2011).	 The	 protein	 also	 shares	 some	 sequence	
homology	to	the	viral	O-acetylesterases,	especially	around	the	active	site	residues	(Arming	







by	 expressing	 ST8Sia1	 and	 Cas1	 proteins	 in	 COS	 cells.	 Interestingly,	 GD3	 synthase	
expression	 alone	 was	 sufficient	 to	 increase	 both	 GD3	 expression	 and	 7-O-acetyl	 GD3	
expression	 (Arming	 et	 al.	 2011).	 This	 indicates	 that	 there	 may	 be	 an	 intrinsic	 O-
acetyltransferase	present	in	these	cells.	GD3	has	also	been	shown	to	be	capable	of	inducing	
its	own	acetylation	(Chen	et	al.	2006).	There	was	however	a	significantly	higher	expression	
of	 7-O-acetyl	 GD3	 when	 cells	 were	 co-transfected	 with	 ST8Sia1	 and	 Cas1.	 In	 both	
experiments	there	was	no	significant	change	in	the	expression	of	9-O-acetyl	GD3	(GD3A)	
indicating	that	Cas1	protein	may	catalyse	only	transfer	of	acetyl	groups	to	the	7	carbon	





acetyl	 GD3.	 In	 another	 study	 by	 Baumann,	 Cas1	 expression	was	 shown	 to	 increase	 the	
expression	of	9-O-acetyl	GD3	in	HEK293T,	LM-TK-	and	HAP	cells.	This	group	suggests	that	





















differs	 in	 the	5’	untranslated	 region	 (UTR),	 and	 its	 first	 coding	exon	 corresponds	 to	 the	
second	of	the	lysosomal	variant	(Orizio	et	al.	2015).	In	the	study	by	Orizio,	RNASeq	data	
was	analysed	from	the	Illumina	Human	body	map	2.0	project.	The	data	indicated	that	in	15	
of	 the	 16	 human	 tissues	 analysed,	 exon-exon	 boundaries	 correspond	 to	 the	 lysosomal	
variant,	while	there	 is	no	transcript	model	supporting	cytosolic	SIAE	(Orizio	et	al.	2015).	
Adult	human	tissue	expression	studies	of	SIAE	transcripts	also	suggest	that	expression	is	
almost	exclusively	 limited	to	the	 lysosomal	SIAE	 isoform.	 It	has	been	suggested	that	the	
cytosolic	variant	of	SIAE	arises	 from	cleavage	of	 the	 lysosomal	variant	 (Takematsu	et	al.	
1999),	but	there	is	little	in	vitro	evidence	of	this.	Despite	its	name,	the	lysosomal	isoform	
of	SIAE	was	not	 found	 in	the	 lysosomal	compartments	 in	experiments	done	by	Orizio	 in	







2010),	 the	 primary	 structure	 of	 the	 SIAE	 protein	 is	 shown	 in	 figure	 1.7	 and	 includes	






sequence	 alignment	 with	 sequences	 from	 32	 protein	 orthologues	 of	 human	 SIAE	 and	
identified	conserved	motifs	and	regions.	The	conserved	regions	were	identified	as	possible	
candidates	 for	 catalytic	 sites	 (Orizio	 et	 al.	 2015).	As	 a	 result	 of	 this	work,	 eleven	highly	
















Phosphorylation	 S30,	 Y31,	 T52,	 S74,	 S79,	 S144,	 S156,	 S158,	
S217,T221,	 S227,	 S228,	 S247,	 S255,	 T303,	









Mutations	 in	 blue	 boxes	 give	 rise	 to	mutations	with	 unknown	effects	 on	 the	 SIAE	
protein.	Mutations	in	yellow	boxes	give	rise	to	SIAE	protein	that	is	associated	with	a	
pathological	 condition	 (M89V	 and	 T312M	 are	 associated	 with	 autoimmunity	 and	
K400N	with	Crohn’s	disease).	Mutations	in	pink	boxes	are	associated	with	defective	





Figure	 1.8	 SIAE	 modifications	 sites	 shown	 as	 part	 of	 the	 homologous	 and	
hypothesised	structure	of	the	SIAE	protein.	N-glycosylation	sites	are	shown	in	red,	











seen,	 confirming	 glycosylation	 was	 responsible	 for	 this	 molecular	 weight	 (Orizio	 et	 al.	
2015).		
It	was	then	explored	whether	glycosylation	was	required	for	activity	of	SIAE,	and	if	it	was	

























































RES256	 and	 UW402	 cells	 were	 obtained	 under	 the	 ethics	 study	 number	 13773	 at	 The	





was	 given	 a	 favourable	 ethical	 opinion	 by	 the national	 research	 ethics	 service	 (NRES)	
committee	South	Central-	Hampshire	A	 (REC	reference	number	11/SC/0048)	 for	a	study	






































































CHLA-01MED	 DMEM	F-12	modification	 20	 ng/mL	 Fibroblast	 Growth	 factor	







Adherent	 cultures	 were	maintained	 by	 removing	media	 and	 washing	 cells	 with	 Hank’s	
balanced	salt	solution	(HBSS;	Gibco)	to	remove	any	FBS,	which	inhibits	the	trypsin	enzyme	
found	in	TrypLE	Express.	Next,	TrypLE	Express	(Gibco),	a	dissociation	reagent,	was	added	
and	 incubated	 on	 the	 cells	 for	 up	 to	 5	minutes	 to	 dissociate	 the	 cells	 from	 the	 plastic	
surface.	 TrypLE	 Express	 was	 then	 neutralised	 with	 growth	 media	 supplemented	 with	
serum.	The	solution	was	aspirated	from	the	flask	and	centrifuged	for	5	minutes	at	300	g	
using	a	Boeco	C-28A	centrifuge.	The	supernatant	was	removed	from	the	pelleted	cells	and	





and	 the	 pellet	 resuspended	 in	 1	mL	 of	 appropriate	 complete	media.	 To	 plate	 cells	 for	
experimental	purposes	10	µL	of	cell	 suspension	was	mixed	with	10	µL	Trypan	Blue	 (Life	














cryovials	 were	 placed	 into	 a	 Mr.	 Frosty	 container	 (Thermo)	 and	 placed	 into	 -80	 OC	





































Mycoplasmas	 are	 a	 species	 of	 bacteria	 that	 are	 resistant	 to	many	 classes	 of	 antibiotics	





Cell	 cultures	 were	 routinely	 tested	 for	Mycoplasma	 infections	 every	 two	 weeks	 using	
MycoAlert	 PLUS	Mycoplasma	Detection	Kit	 (Lonza).	 The	Mycoplasma	assay	exploits	 the	
activity	of	enzymes	found	in	all	six	of	the	most	prevalent	Mycoplasma	species	and	are	not	
































SIAE	 Sheep	anti-human	IgG	 Custom	 made	 (see	 section	
2.7)	
Beta	Actin	 Mouse	anti-human	IgG	 Sigma	(A4700)	








Infrared	700/800	CW	 Goat	 anti-mouse	 and	
Donkey	anti-goat	IgG	


















SIAE	 peptide	 using	 well-established	 software	 (NHLBI-AbDesigner).	 With	 help	 from	 Alta	
Bioscience	 Ltd	 potential	 peptides	 were	 reviewed.	 A	 17	 amino	 acid	 peptide	 sequence	
(SSDLSKKSSDDGFPQIR)	 was	 selected	 for	 optimal	 immunogenicity	 and	 minimal	 cross-
reactivity.	The	SIAE	peptide	was	used	to	produce	antibodies	in	sheep	by	National	health	





The	 quantitative	 expression	 of	 several	 antigens	 was	 determined	 using	 flow	 cytometry.	
Antigens	 were	 either	 intra-	 or	 extracellular	 and	 are	 distinguishable	 through	 a	












cytofix/cytoperm	 solution	 (BD	 Biosciences)	 and	 incubating	 at	 4oC	 for	 20	 minutes.	 The	
cytofix/cytoperm	 solution	 disrupts	 cell	 membranes	 in	 a	 reversible	 manner	 so	 for	
intracellular	 antigen	analysis	 the	 cells	were	 then	kept	 in	 the	presence	of	0.1	%	 saponin	







cytometry	 were	 anti-GD3	 1:50	 (20	 µg/mL)	 and	 anti-9-O-acetyl	 GD3	 1:10	 (10	 µg/mL).	
Autofluorescent,	no	primary	antibody	and	isotype	controls	were	included	at	this	stage.	Cells	






















Cells	were	 seeded	at	200,000	cells	per	well	onto	sterile	glass	 coverslips	 in	6	well	plates	
(Greiner)	 and	 were	 allowed	 to	 adhere	 for	 24	 hours	 at	 37oC	 in	 a	 5	 %	 CO2	 humidified	
atmosphere.	 Cells	 were	washed	with	 PBS	 and	 fixed	 using	 4	%	 paraformaldehyde	 (PFA;	
Sigma)	in	PBS	(Sigma).	Cells	were	then	washed	and	permeabilised	using	0.01	%	Triton	X-
100	 (Sigma)	 in	 PBS	 for	 intracellular	 antigens	 and	 incubated	 for	 10	 minutes	 at	 4oC,	 for	
extracellular	antigens	this	was	omitted.	Cells	were	then	washed	three	times	in	PBS.	Non-
specific	binding	was	blocked	for	1	hour	at	room	temperature	using	500	µL	NGS	in	PBS.	After	
this	 block	 buffer	 was	 aspirated	 and	 each	 sample	 was	 incubated	 with	 500	 µL	 of	 the	
appropriate	primary	antibody	(anti-GD3	1:50	(20	µg/mL	and	anti-9-O-acetyl	GD3	1:100	(1	
µg/mL)	 diluted	 in	 PBS	 containing	 1	%	NGS	 for	 1	 hour	 at	 room	 temperature.	 Cells	were	
washed	three	times	with	PBS.	Alexafluor	conjugated	secondary	antibodies	(diluted	1:500)	
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were	 then	 added	 to	 each	 sample	 using	 the	 appropriate	 species	 and	 isotype.	 A	 500	 µL	
aliquot	of	secondary	antibody	in	PBS	containing	1	%	NGS	was	added	to	each	sample	and	



























To	 determine	 ganglioside	 expression	 in	 the	wild-type	mouse	 frozen	 brain	 sections	 first	
sections	were	fixed	with	4	%	paraformaldehyde	(sigma)	for	30	minutes.	Each	subsequent	
step	was	 carried	 out	 in	wells	 of	 a	 24	well	 tissue	 culture	 plate	 (Greiner).	 Sections	were	













(Vector	 Labs).	 Cells	 were	 then	 imaged	 using	 the	 Zeiss	 Axioimager	 ZI	 epifluorescence	



























endonucleases	 that	 had	unique	 sites	within	 the	 construct.	 For	 cloning	 of	 the	 enhanced	
green	fluorescent	protein	(EGFP)	gene	into	multiple	cloning	site	2	(MCS2)	the	restriction	





















1	 2	 3	 4	 5	
Figure	2.3	pTRE3G-IRES	construct	is	linearised	by	restriction	endonuclease	digestion	run	
on	1%	TAE	agarose	and	run	at	80	V	for	90	mins.	20	µL	of	sample	was	added	to	each	lane	































































To	ensure	 the	EGFP	gene	had	been	 incorporated,	 the	 resulting	DNA	was	digested	once	
again	with	MluI	and	BamHI	and	the	insert	sized	on	an	agarose	gel	as	shown	in	figure	2.4.	
The	 resulting	construct	was	pTRE3G-IRES-EGFP	and	was	 further	cloned	 into	 to	generate	
pTRE3G-IRES-EGFP-SIAE	and	pTRE3G-IRES-EGFP-SIAE_S127A	by	digestion	with	EagI	and	SalI	
enzymes	unique	to	multiple	cloning	site	1	(MCS1).		













100	ng	 0	ng	 2	µL	of	control	 insert	
(Clontech)	
Linearised	vector	 50	ng		 1	µL	 1	uL	of	 control	 pU19	
vector	(Clontech)	










































































All	 plasmids	 were	 plated	 on	 50	 µg/mL	 ampicillin.	 The	 plates	 were	 incubated	 at	 37oC	
overnight	 to	allow	colonies	 to	 form.	The	next	day	plates	were	sealed	with	parafilm	and	
stored	at	4oC	until	colony	selection.		






stocks	 were	 prepared.	 A	 total	 volume	 of	 1.125	 mL	 of	 bacteria	 culture	 was	 added	 to	
duplicate	sterile	screw	top	eppendorf	tubes.	A	volume	of	375	µL	of	sterile	60	%	glycerol	











supernatant	 transferred	 to	 a	 PureYield™	Minicolumn	without	 disturbing	 the	 cell	 debris	




Promega)	was	 then	 added	 to	 the	minicolumn	 and	 centrifuged	 at	maximum	 speed	 in	 a	











G-418	 was	 added	 at	 the	 selection	 concentration	 that	 was	 determined	 from	 kill	 curves	
(appendix	 5).	 The	medium	was	 replaced	 every	 four	 days	 to	 ensure	 presence	 of	 G-418	
remained	constant.	Cells	that	have	not	integrated	the	plasmid	begin	to	die	after	3–5	days.	







transfected	 with	 5	 μg	 of	 pTRE3G-Luc	 using	 Xfect	 transfection	 reagent	 as	 previously	
described.	 After	 4	 h,	 the	 culture	 medium	 was	 replaced	 with	 fresh	 medium	 containing		
1	 µg/mL	 doxycycline	 to	 one	 of	 the	 duplicate	 wells,	 while	 leaving	 the	 second	 well	




































For	 transfection	 with	 pCMV-TetOn3G,	 pTRE3G-Luc,	 pTRE3G-IRES-EGFP,	 pTRE3G-IRES-























Cells	 were	 transiently	 transfected	 with	 each	 construct	 as	 previously	 described	 and	
harvested	using	trypLE	express	(Life	technologies)	as	previously	described.	A	volume	of	96	
μL	of	each	cell	sample	was	added	to	a	microcentrifuge	tube	and	2	μL	of	500	μg/mL	Hoechst	
33342	 was	 added	 and	 mixed	 by	 pipetting	 to	 counterstain	 nuclei.	 The	 cells	 were	 then	
incubated	at	37oC	for	15	minutes	using	a	heat	block.	After	the	incubation	period	2	μL	of	500	
μg/mL	propridium	iodide	was	added	and	mixed	by	pipetting	to	determine	the	dead	cell	






















































lysates	 were	 centrifuged	 at	 maximum	 speed	 (16,900	 g)	 using	 an	 Eppendorf	 5415r	



































A	 0	 300	 of	 stock	 (2	 mg/mL	
BSA)	
2000	
B	 125	 375	of	stock	 15000	
C	 325	 325	of	stock	 1000	
D	 175	 175	of	vial	B	solution	 750	
E	 325	 325	of	vial	C	dilution	 500	
F	 325	 325	of	vial	E	dilution	 250	
G	 325	 325	of	vial	F	dilution		 125	
H	 400	 100	of	vial	G	dilution	 25	


















any	 given	 experiment.	 Each	 experiment	was	 performed	 in	 triplicate.	 After	 the	 required	










buffer	 and	β-mercaptoethanol	 (Sigma)	 at	 an	 appropriate	 concentration	 and	 volume	 for	









was	 hydrated	 for	 15	 seconds	 in	methanol	 (Sigma)	 and	 placed	 into	 transfer	 buffer	 until	
needed.	In	order	to	transfer	the	protein	from	gel	to	PVDF	membrane,	the	sandwich	method	
was	used.	Mini-Blot	filter	paper	(Bio-Rad)	and	2	sponges	were	soaked	in	transfer	buffer	and	















primary	antibody	and	 the	 loading	 control	 antibody.	The	membrane	was	 then	washed	5	
times	with	 Tris-buffered	 saline	 (0.2	mM	Trizma	base;	 1.4	mM	sodium	chloride;	 pH	7.6)	
























repeated.	 The	 cell	 pellet	was	 then	 resuspended	 in	 250	 μL	 of	 1	 μg/mL	 of	DAPI	 solution	
(Satorius).	The	cells	were	then	added	to	an	A2	nucleocounter	slide	(Satorius)	and	analysed	















The	 agents	 chosen	 for	 chemotherapy	 experiments	 were	 cisplatin	 and	 etoposide,	 these	
were	 used	 as	 examples	 of	 cell-cycle	 non-specific	 (cisplatin)	 and	 cell-cycle	 specific	
(etoposide)	agents	currently	in	use	for	treatment	of	brain	tumours	in	children.	Etoposide	
was	 also	 chosen	 for	 its	 reported	 mechanism	 of	 action	 on	 the	 collapse	 mitochondrial	
membrane	potential	in	isolated	mitochondria	(Robertson	et	al.	2000).	As	the	mechanism	


















RNA	 and	 DNA	 polymerases	 cause	 tension	 on	 the	 DNA	 helix	 as	 extension	 takes	 place.		
Topoisomerase	 II	 releases	 tension	 on	 the	 DNA	 helix	 by	 creating	 transient	 double	 strand	
breaks	thereby	relieving	supercoils.	Topoisomerase	 II	 then	 joins	the	breaks	back	together.	
























such	 that	 the	 apoptotic	 program	 is	 initiated.	 Adapted	 from	 Dasari	 &	
Tchounwou,	2014.	
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doxycycline	 treatment,	 when	 SIAE	 expression	 was	 confirmed,	 cells	 were	 treated	 with	
Cisplatin	 (Sigma)	 made	 fresh	 in	 sterile	 PBS	 (Sigma)	 or	 Etoposide	 (Sigma)	 made	 in	
dimethylsulphoxide	(DMSO;	Sigma).		Concentrations	ranged	from	1	μM	to	14	μM	at	1	μM	
increases.	Untreated	cells	and	vehicle	controls	were	 included	for	each	clone	 in	order	 to	
determine	any	changes	in	viability	seen	were	due	to	drug	treatment.		Cells	were	treated	







































































poorer	 prognosis	 subgroups	may	 need	more	 tailored	 therapy	 to	 improve	 their	 survival	
(Gilbertson	2004).	The	refining	of	treatments	for	each	subgroup	is	just	beginning	to	emerge	
as	we	learn	more	about	this	disease.	Medulloblastoma	is	a	tumour	of	development	and	
therefore	 our	 work	 focuses	 on	 a	 pathway	 that	 functions	 in	 the	 development	 of	 the	
cerebellum	(Wechsler-Reya	&	Scott	2001a;	Svennerholm	et	al.	1991;	Miyakoshi	et	al.	2001).	
The	GD3	acetylation	pathway	 is	known	to	have	 roles	 in	brain	development	 (Liang	et	al.	
2011;	Yu	et	al.	2004)	and	 in	malignancies	such	as	high	grade	gliomas	(Birks	et	al.	2011).	


















GD3A	 expression	 plays	 a	 role	 in	 protecting	 cells	 from	 GD3-mediated	 apoptosis,	 we	
predicted	that	SIAE	would	be	expressed	in	high	levels	in	medulloblastoma	subgroups	with	
the	poorest	prognosis.	SIAE	cleaves	acetyl	groups	from	the	carbon	9	position	of	SIAE,	such	





In	 order	 to	 determine	 if	 the	 GD3	 acetylation	 pathway	 was	 abnormally	 expressed	 in	











Figure	 3.1	 The	 major	 components	 of	 the	 GD3	 acetylation	 pathway.	 GD3	 is	
synthesised	from	its	precursor	ganglioside	GM3	by	the	enzyme	ST8Sia1.	The	ST8Sia1	
enzyme	adds	a	second	sialic	acid	residue	to	GM3	via	a	2,8-glycosidic	bond,	forming	
GD3	 (reaction	 1).	 GD3	 can	 be	 acetylated	 to	 9-O-acetyl	 GD3	 (GD3A),	 which	 is	

















unknown	age	at	diagnosis).	Of	 these	patients,	35	had	group	4	 tumours,	 followed	by	33	
patients	 with	 SHH	 subgroup	 tumours,	 27	 patients	 with	 group	 3	 tumours	 and	 finally	 8	
patients	with	WNT	subgroup	 tumours.	 The	distribution	of	 subgroups	was	 similar	 to	 the	
incidence	seen	in	the	clinic	(Northcott,	Korshunov,	et	al.	2012).	




its	 precursor	 GM3.	 ST8Sia1	 mRNA	 was	 found	 to	 be	 significantly	 down-regulated	 in	
medulloblastoma	 tissue	 compared	 to	 non-neoplastic	 foetal	 and	 adult	 brain	 (p<0.0001)	
(figure	3.2A).		
Cas1	is	the	enzyme	hypothesised	to	catalyse	the	acetylation	of	GD3	to	GD3A	(reaction	2;	





however	 must	 be	 taken	 into	 consideration	 along	 with	 the	 deacetylation	 enzyme	 SIAE	
(Mukherjee	et	al.	2008;	Mandal	et	al.	2012),	SIAE	cleaves	the	acetyl	groups	from	sialic	acid	
residues	at	the	carbon	4	and	carbon	9	positions,	such	as	those	found	in	GD3A	(Orizio	et	al.	


















neoplastic	 foetal	 and	 adult	 brain	 samples	 (p<0.0001).	 (B)	 Cas1	 mRNA	 encoding	 the	
hypothesised	 acetylation	 enzyme	 of	 GD3	 was	 found	 to	 be	 significantly	 up-regulated	 in	
medulloblastoma	 samples	 compared	 to	 non-neoplastic	 foetal	 and	 adult	 brain	 samples	
(p<0.0001).	 (C)	 SIAE	mRNA	 encoding	 the	 acetyl	 esterase	 enzyme	 of	 GD3	was	 found	 to	 be	




regulated	 in	 medulloblastoma	 (reaction	 1;	 green	 arrow).	 Cas1,	 the	 acetyl	 transferase	
















the	 molecular	 subgroups	 was	 then	 explored	 using	 a	 similar	 bioinformatics	 approach.	





expression	 of	 the	 regulators	 of	 the	 GD3	 and	 GD3A	 pathway	 between	 subgroups	 of	
medulloblastoma.		
ST8Sia1	 mRNA	 was	 lowest	 in	 the	 WNT	 subgroup	 compared	 to	 the	 highest	 level	 of	















was	 therefore	 considered.	 This	 catalytic	 step	 is	 shown	 as	 part	 of	 the	 GD3	 acetylation	
pathway	in	figure	3.3.	ST8Sia5	is	a	more	promiscuous	enzyme	and	can	convert	GD3	into	
GT3	 by	 the	 addition	 of	 a	 sialic	 acid	 residue,	 or	 it	 can	 convert	GD3	 to	GD2	 through	 the	





























Figure	 3.4	 ST8SIa1	 and	 ST8Sia5	 expression	 varies	 with	 molecular	 subgroup	 of	




using	 the	 same	dataset	 and	 shows	 that	 there	 are	 significant	 differences	 in	 expression	
between	 the	 less	 aggressive	 subgroups	 WNT	 and	 SHH	 which	 demonstrated	 higher	

















was	 characterised	 in	 subgrouped	 samples	 and	 shows	 highest	 expression	 in	 group	 4	
disease	and	the	lowest	expression	is	seen	in	the	WNT	and	SHH	subgroup	samples.	(B)	The	
level	of	SIAE	mRNA	 (the	human	endogenous	deacetylation	enzyme	of	GD3A)	was	also	
characterised	 in	 subgrouped	 medulloblastoma	 samples	 at	 the	 mRNA	 level.	 The	
expression	of	SIAE	was	highest	in	the	WNT	subgroup	compared	to	all	other	subgroups.	
Data	obtained	from	the	R2	database	using	the	Northcott	(core	Transcript)	data	set.	Data	








Figure	 3.6	 A	 summary	 of	 the	mRNA	expression	of	 the	 regulating	 enzymes	 of	 the	GD3	
acetylation	 pathway	 by	molecular	 subgroup.	 The	 expression	 of	 GD3	 is	 determined	 by	
ST8Sia1,	 the	enzyme	which	converts	GM3	 to	GD3,	and	 the	enzyme	 that	uses	GD3	as	a	





respect	 to	 non-neoplastic	 brain	 tissue	 as	 this	 data	 was	 not	 available	 (dotted	 arrows	
represent	 unknown	 relationship	 to	 non-neoplastic	 brain	 controls)	 and	 we	 therefore	
cannot	 conclude	 that	mRNA	 levels	 of	 ST8Sia5	 are	 down-regulated	 in	medulloblastoma	
samples.	 We	 also	 confirmed	 higher	 expression	 of	 Cas1,	 the	 hypothesised	 acetylation	
enzyme	 of	 GD3	 in	 group	 3	 and	 group	 4	 disease	 compared	 to	WNT	 and	 SHH	 samples,	
suggesting	that	there	may	be	higher	levels	of	GD3A	expression	in	these	subgroups	(green	
box;	 reaction	 2).	 In	 agreement	 with	 this,	 the	 mRNA	 levels	 of	 SIAE	 (the	 deacetylation	
enzyme	of	GD3A)	show	low	levels	of	SIAE	mRNA	in	group	3	and	group	4	disease,	and	in	this	
case	 in	SHH	disease	as	well,	suggesting	that	GD3A	may	be	expressed	 in	higher	 levels	 in	
these	 subgroups.	 Data	 obtained	 from	 the	 R2	 database	 using	 the	 Northcott	 (core	
Transcript)	data	set.			
166	



























significant	 differences	 found	 between	 any	 other	 subgroup	 demonstrating	 that	 the	
expression	of	SIAE	mRNA	was	similar	between	SHH,	group	3	and	group	4.	































For	 this	 study,	 publically	 available	 data	 was	 mined	 from	 the	 R2	 database	 using	 the	
Heidelberg	data	set,	this	microarray	was	carried	out	on	a	custom	chip	set	and	normalised	





ST8Sia1	 which	 synthesises	 GD3	 from	 GM3	 (reaction	 1;	 figure	 3.1).	 ST8Sia1	 was	 down-
regulated	as	shown	by	negative	transformed	log-fold	values	(figure	3.7A).	The	expression	
of	ST8Sia1	appeared	to	be	correlated	with	metastatic	stage	from	M1	to	M3,	however	the	
highest	 level	 of	 expression	 seen	 in	 M0.	 There	 was	 however	 no	 significant	 difference	
between	metastatic	stages	(figure	3.7A).		




at	 the	 mRNA	 level	 is	 shown	 to	 increase	 with	 increasing	 M	 stage	 (figure	 3.8A).	 The	
expression	of	Cas1	 is	 significantly	higher	 in	 the	M3	stage	compared	 to	M0	 (p<0.05).	The	
expression	of	SIAE,	the	deacetylation	enzyme	of	GD3A,	is	decreased	at	the	mRNA	level	with	
increasing	M	 stage	 and	 is	 shown	 to	 be	 lowest	 in	M3	 disease	 compared	 to	M0	 and	M1	






































Figure	 3.7	 mRNA	 levels	 of	 ST8Sia1	 and	 ST8Sia5	 according	 to	 metastatic	 stage.	
Expression	 of	 ST8Sia1,	 the	 enzyme	 that	 synthesises	 GD3	 from	 GM3,	 was	 similar	
between	 all	metastatic	 stages	 as	 there	was	 not	 significant	 difference	 in	 expression	
between	 any	 metastatic	 stage.	 (B)	 mRNA	 expression	 of	 ST8Sia5	 appears	 to	 be	































































the	 expression	 of	 GD3	 when	 analysed	 alone.	 Cas1	 is	 significantly	 up-regulated	 in	 the	








higher	 in	 the	 WNT	 subgroup	 compared	 to	 group	 3	 (p<0.0001)	 and	 group	 4	 (p<0.001)	
suggesting	that	the	more	aggressive	subgroups	would	be	more	likely	to	have	higher	levels	
of	GD3.	This	was	also	the	case	for	the	SHH	subgroup	which	expressed	significantly	more	




gangliosides	 than	 group	 3	 and	 group	 4	 tumours,	 however	 this	 would	 need	 further	
exploration	to	confirm	this	hypothesis.		
In	 terms	 of	medulloblastoma	 subgroups,	 data	 also	 show	 the	 highest	 level	 of	 Cas1	 and	
lowest	 expression	 of	 SIAE	 are	 found	 in	 group	 3	 and	 group	 4	medulloblastomas.	 This	 is	
supportive	 of	 the	 hypothesis	 that	 the	 balance	 of	 GD3	 to	 GD3A	 is	 in	 favour	 of	 GD3A,	
particularly	in	the	more	aggressive	subgroups	of	disease.	When	this	data	was	examined	in	
relation	 to	metastatic	 stage	 the	prediction	 that	with	 increasing	M	 stage	GD3	and	GD3A	
expression	would	increase,	in	favour	of	GD3A	was	also	supported.		




compared	 to	M0	 (p<0.05).	 The	expression	of	Cas1	and	SIAE	were	 found	 to	be	 inversely	
correlated,	particularly	 in	M3	disease.	 The	data	 suggest	 that	with	 increasing	M	stage	of	
disease	the	expression	of	GD3	to	GD3A	is	likely	to	be	in	favour	of	GD3A	as	the	expression	of	
Cas1	is	up-regulated,	the	expression	of	SIAE	is	concomitantly	down-regulated.	
In	 summary,	 these	 findings	 support	 the	 idea	 that	 GD3	 is	 likely	 to	 be	 re-expressed,	
particularly	in	the	higher	risk	disease	groups	(groups	3	and	4,	and	high	M	stage)	and	is	also	
likely	to	be	acetylated	to	GD3A	in	medulloblastoma.	Therefore,	we	characterised	the	GD3	
and	 GD3A	 expression	 in	 medulloblastoma	 cell	 lines	 to	 compliment	 the	 bioinformatics-








The	expression	of	GD3	and	GD3A	has	been	shown	to	be	 in	delicate	balance	 in	 favour	of	
GD3A	 in	 cancers	 such	 as	 acute	 lymphoblastic	 leukaemia	 (Mukherjee	 et	 al.	 2008)	 and	
glioblastoma	 multiforme	 (Birks	 et	 al.	 2011).	 In	 this	 part	 of	 the	 study	 we	 aimed	 to	
characterise	these	gangliosides	in	three	medulloblastoma	cell	lines	(RES256,	UW402	and	
CHLA-01-Med)	 in	order	to	determine	the	relevance	of	this	pathway	in	this	tumour	type.	
Based	 on	 bioinformatics	 data,	 the	 expression	 of	 GD3	 and	 GD3A	 may	 be	 expressed	 by	









Expression	 levels	 were	 determined	 by	 directly	 assaying	 GD3	 and	 GD3A	 to	 determine	
expression	of	the	products,	not	the	mRNA	of	the	synthesis	enzymes.	Flow	cytometry	was	
used	 to	determine	quantitative	expression	of	both	antigens	 as	 a	percentage	of	 the	 cell	
175	
population,	 and	 was	 further	 confirmed	 with	 qualitative	 immunocytochemistry.	 A	
representative	example	of	positive	staining	is	shown	in	figure	3.9A.		
The	 expression	 of	 cell	 surface-associated	 and	 intracellular	 GD3	 and	 GD3A	 were	
characterised	 and	 compared	 in	medulloblastoma	 cell	 lines	 using	 flow	 cytometry.	 Three	
medulloblastoma	cell	lines	RES256,	UW402,	and	CHLA-01-Med	were	used	and	compared	













mediated	apoptosis	at	 low	 levels	 (Kniep	et	al.	2006).	Expression	of	both	antigens	 in	 the	
























cytometry	 histograms	 demonstrating	 expression	 of	 GD3	 and	 GD3A.	 Purple	 filled	 peaks	
represent	negative	control	samples	from	which	gating	was	carried	out,	red	peaks	represent	
positive	staining.	Histograms	represent	one	technical	replicate	from	one	experiment.	 	 (B)	
Intracellular	 expression	 of	 GD3	 and	 GD3A	 from	 three	 independent	 experiments	
demonstrates	a	higher	level	of	GD3A	expression	(red	bars)	compared	to	GD3	(green	bars)	in	
CHLA-01-Med,	a	group	4	cell	line.		(C)	Cell	surface	expression	of	GD3	and	GD3A	shows	a	higher	





To	 further	 confirm	 the	 expression	 of	 GD3	 and	 GD3A	 in	 medulloblastoma	 cell	 lines,	















































































however	 background	 fluorescence	 in	 this	 instance	making	 the	 actual	 staining	 intensity	 of	
GD3A	difficult	 to	determine.	 taken	using	a	Zeiss	Axioimager	ZI	epifluorescence	microscope	
































An	 inducible	 system	was	used	 to	 control	 SIAE	 transcript	 expression.	 These	experiments	
were	 designed	 to	 test	 our	 hypothesis	 that	 over-expression	 of	 SIAE	 would	 result	 in	 an	
increase	 in	 GD3A	 deacetylation.	 This	 GD3A,	 when	 deacetylated,	 was	 hypothesised	 to	
increase	 the	 pool	 of	 GD3	 which	 may	 then	 result	 in	 a	 collapse	 of	 the	 mitochondrial	





we	 cannot	 conclude	 from	 this	 data	 that	 SIAE	 overexpression	 was	 toxic	 to	 cells,	 we	
concluded	that	a	well	described	inducible	system	approach	would	provide	us	with	a	model	
to	directly	 test	our	hypothesis	 that	SIAE	overexpression	 leads	 to	deacetylation	of	GD3A.		






The	 catalytic	 mutant	 SIAE-S127A	 has	 been	 described	 by	 several	 groups	 who,	 when	
investigating	 the	 possible	 sites	 for	 the	 catalytic	 triad	 of	 SIAE,	 conducted	 site-directed	
mutagenesis	 studies	 that	 demonstrated	 serine	 127	 (S127)	 as	 a	 conserved	 and	 critical	
residue	 for	 esterase	 activity	 (Surolia	 et	 al.	 2010;	Orizio	 et	 al.	 2015).	 These	 studies	 also	









to	 alanine	 mutation	 and	 is	 shown	 at	 positions	 378-380	 of	 the	 cDNA	 sequence	
(corresponding	to	amino	acid	127).		
The	 incorporation	of	 the	EGFP,	 SIAE	and	SIAE-S127A	genes	was	 successful	 as	 shown	by	










Figure	 3.13	 Sanger	 sequencing	 demonstrates	 that	 SIAE	 and	 SIAE-S127A	 genes	were	
successfully	 cloned	 into	 the	 pTRE3G-IRES-EGFP	 plasmids.	 The	 mutation	 encoding	














CMV	 promoter.	 In	 the	 presence	 of	 doxycycline,	 Tet-On	 3G	 protein	 undergoes	 a	
conformational	 change	 that	 allows	 binding	 to	 the	 PTRE3G	 promoter	 (figure	 3.14).	 The	


























Figure	 3.15	 Two	 proteins	 are	 expressed	 from	 one	 mRNA	 transcript	 using	 an	 internal	
ribosomal	entry	site.	The	Tet-On	3G	inducible	system	contains	an	internal	ribosomal	entry	
site	(IRES)	under	the	control	of	a	tet-responsive	promoter	(PTRE3G).	Gene	expression	is	only	


















Luciferase	 kit	 (Promega).	 The	 assay	was	 carried	out	 and	 luminescence	of	 the	 luciferase	
protein	 recorded.	 Fold-induction	 of	 expression	 was	 confirmed,	 and	 the	 clones	 which	
demonstrated	the	lowest	basal	expression	and	the	highest	induction	of	expression	were	
propagated	(appendix	4).	
The	 clones	 with	 the	 highest	 fold-induction	 of	 luciferase	 gene	 expression	 were	 then	
transfected	with	pTRE3G-IRES-EGFP	(empty	vector	control),	pTRE3G-IRES-EGFP-SIAE	(wild-










acid	 assay	 (BCA	 Assay;	 Thermo).	 Protein	 was	 separated	 using	 polyacrylamide	 gel	
electrophoresis	 and	 transferred	 to	 a	 PVDF	 membrane	 and	 prepared	 for	 Western	 blot	
analysis	using	an	in-house	anti-SIAE	antibody	(described	in	chapter	2).	Two	wild-type	clones	














equipped	 with	 a	 Hamamatsu	 digital	 camera	 and	 velocity	 imaging	 software.	 40	 X	
magnification,	scale	bar	100	µm.	n=3	
194	
In	 RES256	 cell	 lysates	 SIAE	 expression	was	 confirmed	by	Western	blot	 analysis	 and	 the	
expression	appeared	to	be	tightly	controlled	(as	demonstrated	by	the	absence	of	construct	
leakiness).	 This	 further	 confirmed	 the	 results	 from	 the	 luciferase	 assay	 that	 the	
conformational	change	of	the	TetOn	3G	protein	was	under	tight	control	(appendix	4.2).	The	







weight	 band,	 which	 is	 more	 intense	 in	 wild-type	 expressing	 clones,	 has	 a	 predicted	
molecular	weight	of	32	kDa.	Initially	we	thought	that	the	blot	may	be	showing	heavy	and	
light	chains	of	the	antibody	we	used,	however	as	we	did	not	see	these	bands	in	our	EGFP	









were	 cultured	 in	 the	 presence	 and	 absence	 of	 doxycycline	 for	 48	 hours	 and	 lysed	 using	
mammalian	 protein	 extraction	 reagent	 containing	 protease	 and	 phosphatase	 inhibitors.	
Protein	was	quantified	using	bicinchoninic	acid	assay	(BCA	assay)	and	was	then	loaded	and	
resolved	 using	 sodium	 dodecyl	 sulphate	 polyacrylamide	 gel	 electrophoresis	 (SDS-PAGE).	












We	 also	 considered	 whether	 the	 62	 kDa	 protein	 might	 be	 secreted.	 Orizio	 et.	 al	
demonstrated	 that	 the	 62	 kDa	 glycoprotein	 can	 be	 secreted	 in	 a	 cell-type	 dependent	
manner.	 This	 publication	 also	 demonstrated	 that	 the	 catalytic	 mutant	 secreted	 more	
enzyme	than	wild-type	in	their	cell	lines	so	we	hypothesised	that	our	mutant	would	do	the	
same.	In	order	to	test	this,	we	first	serum-depleted	the	cells	over	48	hours.	We	then	treated	
with	 doxycycline	 for	 48	 hours	 as	 for	 pervious	 experiments.	 Conditioned	 media	 was	
harvested	and	analysed	by	Western	blot	analysis	(figure	3.18).	Protein	loading	was	adjusted	
and	 confirmed	 with	 Ponceau	 S	 staining	 (figure	 3.18B).	 The	 conditioned	 media	 studies	











after	 which	 media	 was	 supplemented	 with	 (or	 without)	 doxycycline	 for	 48	 hours.	
Conditioned	 media	 was	 then	 loaded	 and	 resolved	 using	 sodium	 dodecyl	 sulphate	
polyacrylamide	gel	electrophoresis	 (SDS-PAGE).	Resolved	protein	was	then	transferred	
onto	a	polyvinylidene	 fluoride	(PVDF)	and	(B)	 stained	with	ponceau	s	 to	ensure	equal	
loading.	 (A)	 The	membrane	was	 then	blocked	 and	probed	with	 an	 in-house	 anti-SIAE	
primary	antibody	 and	 conjugated	 fluorescent	 secondary	antibody.	 	 SIAE	was	 secreted	
only	by	by	the	catalytic	mutant,	S127A,	importantly	only	when	the	cells	were	cultured	















analysis	 we	 showed	 the	 cleavage	 product	 to	 have	 a	 molecular	 weight	 of	 32	 kDa;	 this	

































The	 database	 generated	 a	 structure	 of	 74%	 of	 the	 SIAE	 sequence	with	 >90%	 accuracy	
indicating	a	good	quality	in	the	prediction.	The	Phyre	2	software	also	generated	a	protein	
database	file	(PDB	file)	which	was	modelled	using	MacPyMol	to	visualise	the	hypothesised	
protein	 structure	 (figure	 3.21).	 Using	MacPyMol,	 the	 sequence	 of	 antibody	 recognition	
(figure	3.21,	green),	the	active	site	residue	mutated	in	in	the	S127A	mutant	(figure	3.21,	
red)	 and	 the	potential	 caspase	1	 cleavage	 site	 (figure	3.21,	 pink)	were	highlighted.	 The	


















Calpastatin,	 X-linked	 inhibitor	 of	 apoptosis	 (XIAP)	 and	 BH3	 interacting-domain	 death	
agonist	 (Bid).	 If	 caspase	 1	 has	 a	 role	 in	 neuronal	 cell	 death	 it	 may	 play	 a	 role	 in	



















Figure	 3.21	 A	 homologous	 SIAE	 structural	 model	 predicts	 the	 caspase	 1	 cleavage	
sequence	is	accessible	to	caspase	1.	(A-B)	The	predicted	SIAE	model	is	based	on	the	amino	
acid	 sequence	 of	 human	 SIAE	 and	 is	 based	 on	 known	 structures	 with	 homologous	
sequences	to	SIAE	generated	by	the	protein	fold-recognition	server	Phyre2.	MacPyMol	
was	used	 to	generate	 the	 image	of	SIAE	which	 is	based	on	Phyre2	prediction.	Phyre2	
shows	 74%	 of	 the	 protein	 was	modelled	 with	 >90%	 confidence	 giving	 the	 structures	
above.	With	a	confidence	of	>90%	the	program	states	that	the	overall	fold	of	the	protein	
(and	 the	 core	 of	 the	 protein)	 is	 modelled	 at	 high	 accuracy	 (2-4Å	 root-mean-square	
deviation	of	atomic	positions	(rmsd)	from	the	native,	true	structure)	however,	surface	
unstructured	loops	may	deviate	from	the	actual	structure.	(A)	Surface	structure	of	SIAE	
as	modelled	by	MacPyMol	using	 a	Phyre	2	 generated	 sequence	 shows	 the	 active	 site	
serine	 residue	 (red),	 the	 in-house	 antibody	 recognition	 sequence	 (green)	 and	 the	
potential	caspase	1	cleavage	site	(pink).	(B)	The	hypothesed	surface	structure	of	SIAE	is	







described	 below	 in	which	we	 tested	 the	 deacetylation	 of	GD3A	 and	 the	 role	 of	 SIAE	 in	





induce	 gene	 expression.	 These	 cell	 lines	 were	 then	 harvested	 for	 assays	 in	 order	 to	
determine	changes	in	the	GD3	and	GD3A	expression	as	well	as	cell	viability	and	response	to	
chemotherapy.		














explored	with	 a	 time	 course	 experiment	 to	 determine	when	GD3A	 cleavage	was	 taking	
place,	if	at	all.		
Another	possible	explanation	for	this	lack	of	significant	changes	in	GD3A	expression	is	that	






expression	 (p<0.05;	 figure	3.22A)	however	 this	was	not	 reflected	by	an	 increase	 in	GD3	









cells	 with	 a	 lower	 (although	 not	 significantly	 lower)	 level	 of	 GD3	 expression	 than	 cells	
cultured	 in	 the	 absence	 of	 doxycycline	 suggesting	 that	 SIAE-S127A	 may	 not	 only	 be	



































the	pool	of	GD3	would	be	 increased	with	 the	 removal	of	acetyl	 groups	 from	GD3A.	 (B)	GD3	
expression	 was	 significantly	 increased	 in	 SIAE	 clone	 2	 in	 wild-type	 expressing	 RES256	 cells	
compared	to	controls	indicating	that	GD3A	cleavage	may	be	occurring.	This	was	not	the	case	in	
clone	1,	nor	the	catalytic	mutant	cell	 line	SIAE-S127A	which	did	not	have	an	 increase	 in	GD3	
expression	which	likely	means	that	GD3A	cleavage	was	not	occurring.	The	wild-type	expressing	
cells	expressed	more	GD3	than	the	catalytic	mutant	cell	line	in	the	presence	of	doxycycline.		In	
EGFP	expressing	cells	 there	was	no	 increase	 in	GD3	expression,	which	may	 indicate	that	the	
reduction	in	GD3A	expression	may	be	due	to	something	other	than	cleavage	of	the	acetyl	group.	




















SIAE	 clone	 2	 nor	 the	 catalytic	 mutant	 SIAE-S127A,	 nor	 the	 empty	 vector	 control	 EGFP	
(p>0.05;	figure	3.23).		
Despite	the	significant	increase	in	depolarisation	with	induction	of	SIAE	expression	in	SIAE	
clone	 1,	 the	 starting	 membrane	 polarisation	 of	 these	 cells	 appears	 very	 high	 (i.e.	 the	
samples	are	mostly	depolarised	at	the	start	of	the	experiment).	This	means	that	this	data	






























The	 effects	 of	 aggressive	 treatment	 of	medulloblastoma	 on	 the	 developing	 brain	 often	
result	 in	 life-long	 treatment	 induced	 side	 effects	 such	 as	 neurocognitive	 deficits	 and	
endocrine	disorders	(Millard	&	De	Braganca	2015).	It	may	provide	benefit	to	patients	if	the	
dose	of	 chemotherapy	 could	be	 lowered,	without	 compromising	 survival.	We	 therefore	
examined	 if	 SIAE	 overexpression	 could	 make	 RES256	 cells	 more	 sensitive	 to	
chemotherapeutics	in	either	a	synergistic	or	additive	way.		Two	drugs	that	are	commonly	
used	 in	 medulloblastoma	 treatment	 regimens	 were	 chosen	 for	 testing,	 cisplatin	 and	
etoposide.		
Etoposide	 is	 a	 drug	 that	 prevents	 transcription	 and	 DNA	 replication	 in	 a	 cell-cycle	
dependent	manner.	 It	 works	 via	 inhibition	 of	 topoisomerase	 II.	 Topoisomerase	 II	 is	 an	
enzyme	that	unwinds	DNA	to	allow	transcription	and	DNA	replication	by	causing	transient	
double	strand	DNA	breaks.	These	breaks	 relieve	 the	 tension	on	DNA	generated	by	DNA	




Cisplatin	 was	 also	 used	 to	 determine	 if	 SIAE	 overexpression	 sensitised	 RES256	 cells	 to	
treatment.	 Cisplatin	 is	 a	 cell-cycle	 non-specific	 DNA	 alkylating	 drug	 that	 causes	 DNA	





In	 order	 to	 test	 our	 hypothesis	 that	 SIAE	 overexpression	 makes	 RES256	 cells	 more	
susceptible	to	cell	death	when	treated	with		etoposide	or	cisplatin,	cells	were	treated	with	
a	 range	 of	 concentrations	 of	 drug	 (or	 vehicle	 control)	 in	 the	 presence	 and	 absence	 of	
doxycycline.	Cells	were	pre-treated	for	48	hours	with	(or	without)	doxycycline	to	allow	gene	
expression	 to	 be	 induced	 before	 the	 chemotherapeutic	 was	 added.	 Doxycycline	 was	
maintained	in	the	media	throughout	the	experiment	where	appropriate.	MTS	assays	were	






















with	 induction	 of	 gene	 expression	 in	 any	 of	 the	 four	 clones.	 (B)	 48	 hour	 treatment	with	
cisplatin	 shows	no	changes	 in	viability	with	expression	of	EGFP.	A	 significant	decrease	 in	
viability	was	seen	with	3	µM	cisplatin	treatment	in	SIAE	clone	1.	This	effect	was	not	seen	



















Figure	 3.25	 RES256	 clones	 are	 treated	 with	 etoposide	 after	 induction	 of	 gene	
expression	 using	 doxycycline.	 (A)	 24	 hour	 treatment	 with	 etoposide	 shows	 no	
significantly	changes	in	cell	viability	in	any	of	the	four	clones	except	EGFP	expressing	
cells	 treated	 with	 1	 µM	 etoposide,	 this	 effect	 however	 is	 not	 maintained	 with	






significant	 decreases	 in	 cell	 viability	 when	 treated	 with	 etoposide.	 (C)	 72	 hour	
treatment	with	etoposide	showed	no	significant	changes	in	cell	viability	in	any	of	the	
four	clones	except	EGFP	expressing	cells	treated	with	1	µM	etoposide,	however	this	







cisplatin	 in	 wild-type	 SIAE	 clone	 1	 (p<0.001)	 but	 this	 effect	 was	 not	 concentration-
dependent	 and	was	 not	maintained	with	 higher	 doses	 (figure	 3.24B).	 There	was	 also	 a	
significant	reduction	in	cell	viability	of	S127A	expressing	cells	with	cisplatin	treatment	with	
4	and	11	μM	(p<0.05;	figure	3.24B)	and	with	12	μM	cisplatin	(p<0.01;	figure	3.24B).	After	








μM	treatment	 (p<0.01;	 figure	3.25A).	 In	SIAE	wild-type	expressing	cells	 (clone	2)	12	μM	
etoposide	treatment	also	had	a	significant	difference	with	gene	expression	(p<0.01;	figure	






After	72	hours	of	 cisplatin	 treatment	 there	was	a	 significant	difference	1	μM	etoposide	
treated	cells	(p<0.05;	figure	3.25C)		
Together	 this	 suggests	 that	 SIAE	 expression	 may	 have	 an	 effect	 on	 cell	 survival	 when	
treated	with	cisplatin	and	etoposide,	particularly	with	48	and	72	hr	treatments.	This	data	
will	be	analysed	further	in	section	3.6.3	to	see	if	there	is	a	change	in	IC50	with	treatment	of	








towards	 reduced	 cell	 viability	 with	 induction	 of	 gene	 expression	 and	 therefore	








































after	 treatment	 of	 cisplatin	 no	 significant	 differences	 are	 seen	 when	 protein	 expression	 is	
induced	 with	 doxycycline	 treatment.	 Data	 analysed	 using	 the	 sigmoidal	 dose-response	 EC50	















































shown	 to	 be	 lowest	 in	 the	 higher	M	 stage	 subgroups	 which	 further	 indicates	 that	 the	
expression	of	GD3A	is	likely	to	be	highest	in	this	subset	of	patients.		
When	explored	in	medulloblastoma	cell	lines,	the	expression	of	GD3	and	GD3A	was	seen	at	
high	 levels.	The	expression	of	 these	two	gangliosides	 is	 in	 favour	of	GD3A.	 In	SIAE	over-
expression	studies	the	highest	expresser	of	GD3A,	RES256	was	transfected	with	inducible	
constructs.	SIAE	over-expression,	but	not	expression	of	the	catalytic	mutant	nor	the	empty	
vector	 control,	 led	 to	 the	depolarisation	of	 the	mitochondrial	membrane	potential.	 The	
expression	of	SIAE	also	caused	the	RES256	cells	to	be	more	susceptible	to	treatment	with	
etoposide	but	not	cisplatin,	chemotherapeutics	commonly	used	to	treat	medulloblastoma.	
In	 light	 of	 this	 work,	 the	 GD3	 acetylation	 pathway	 may	 have	 an	 important	 role	 in	







2004)	 and	 in	malignancies	 such	 as	 high	 grade	 gliomas	 (Birks	 et	 al.	 2011).	 Of	 particular	
interest	to	this	project	is	GD3’s	role	in	the	developing	cerebellum.	GD3	is	expressed	by	the	







show	 here,	 in	 medulloblastomas,	 GD3	 becomes	 re-expressed.	 In	 acute	 lymphoblastic	
leukaemia	 (ALL),	 high	 levels	 of	 GD3	 have	 been	 shown	 to	 protect	 from	 a	 pro-apoptotic	
phenotype,	 due	 to	 acetylation	 of	 GD3	 (GD3A).	 GD3A	 can	 protect	 from	 GD3-mediated	


















with	 the	 GD3A	 acetyl	 esterase	 enzyme	 haemagluttanin	 esterase	 (HE)	 demonstrated	 a	
reduction	of	viability	when	cleavage	of	GD3A	occurred	(Birks	et	al.	2011).	With	cleavage	of	







et	 al.	 2006).	 When	 GD3A	 is	 present	 it	 has	 been	 shown	 that	 GD3A	 cannot	 induce	
mitochondrially-mediated	 apoptosis	 and	 furthermore	 suppresses	 the	 ability	 of	 GD3	 to	
induce	apoptosis	itself	(Malisan	et	al.	2002).	GD3A	expression	has	been	shown	to	protect	
cells	from	chemotherapeutic	insult,	and	also	from	endogenously	added	GD3,	even	at	very	









(Yu	 et	 al.	 2004)	 and	 the	 major	 players	 in	 the	 turnover	 of	 the	 gangliosides	 have	 been	
discovered	 in	 recent	 years.	 The	 enzyme	 that	 synthesises	GD3	 is	 ST8Sia1,	 the	 gene	 that	
encodes	this	enzyme	is	located	on	chromosome	12	at	12p12.1.	In	Yu	et.	al’s	study,	it	was	
stated	that,	assuming	the	concentration	of	the	substrate	of	ST8Sia1	(GM3)	is	in	constant	
supply,	 the	 outcome	 (GD3	 expression)	 is	 dependent	 on	 the	 enzyme	 that	 catalyses	 its	
synthesis,	and	the	enzyme	that	consumes	the	ganglioside	intermediate	(Yu	et	al.	2004).	In	
other	words,	to	increase	the	expression	of	the	ganglioside	GD3,	the	cell	has	to	express	the	
ganglioside	 (via	 ST8Sia1	 expression	or	 increased	 ST8Sia1	 activity)	 but	 also	decrease	 the	
expression	(or	activity)	of	the	enzyme	that	uses	it	as	a	substrate	(ST8Sia5).			
Another	enzyme	that	regulates	this	pathway	is	the	human	endogenous	acetyl-transferase	
enzyme	 Cas1,	 whose	 encoding	 gene	 is	 located	 on	 chromosome	 7	 at	 7q21.3.	 Cas1	 is	
hypothesised	to	play	a	role	in	the	acetylation	of	GD3	(Arming	et	al.	2011).	There	is	 little	
known	about	this	enzyme	and	its	roles	in	vivo,	however	a	recent	study	by	(Baumann	et	al.	
2015),	 showed	 that	 knock-down	 of	 the	 Cas1	 gene	 CASD1	 using	 clustered	 regularly-
interspaced	 short	 palindromic	 repeat/	 crispr-associated	 protein	 (CRIPSR/Cas)	 genome	
editing,	 abolished	 GD3	 acetylation	 in	 HAP1,	 HEK293T	 and	 CHO	 cells	 when	 cells	 also	
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expressed	 ST8Sia1.	 	 This	 study	 provides	 evidence	 for	 the	 involvement	 of	 Cas1	 in	 GD3	
acetylation.	
The	 final	enzyme	 thought	 to	play	a	 role	 in	 the	 regulation	of	 this	pathway	 is	 the	human	
endogenous	 deacetylation	 enzyme	 SIAE,	 whose	 gene	 is	 located	 on	 chromosome	 11	 at	
11q24.2.	SIAE	is	known	to	regulate	the	expression	of	GD3	and	GD3A	and	has	been	described	
in	 acute	 lymphoblastic	 leukaemia	 (ALL)	 (Mandal	 et	 al.	 2012).	 SIAE	 has	 been	 shown	 to	





that	 in	 pre-B	 acute	 lymphoblastic	 leukaemia	 cells	 this	 treatment	 proved	 to	 be	 lethal	
(Parameswaran	et	al.	2013).			
4.4 GD3	 synthesis	 enzymes	 are	 atypically	 expressed	 in	medulloblastoma	
across	subgroups	and	metastatic	stages	












et	al.	 2004).	When	 the	 samples	were	analysed	according	 to	molecular	 subgroup	 (figure	
3.4A)	 there	was	a	 significantly	 lower	expression	of	 ST8Sia1	 found	 in	 the	best	prognosis	
subgroup,	WNT,	compared	to	SHH	and	group	4	(p<0.0001).	This	difference	in	expression	














of	 ST8Sia1.	 Group	 3	 expression	 was	 found	 to	 be	 significantly	 lower	 than	 the	 rarely	
metastatic	 SHH	subgroup	 (p<0.0001),	which	had	 the	highest	expression	of	 ST8Sia1.	The	
expression	of	ST8Sia1	was	similar	in	group	3	and	group	4	samples.		
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When	 the	 expression	 of	 ST8Sia1	 was	 examined	 at	 the	 metastatic	 stage	 (figure	 3.7A),	
expression	was	low	overall	but	highest	expression	was	seen	in	the	M3	stage	of	disease.	This	












When	 the	 expression	 of	 this	 enzyme	 was	 explored	 at	 the	 M	 stage	 (figure	 3.7B),	 the	
expression	was	expected	to	be	lowest	in	the	most	metastatic	subgroup	M3	as	this	would	















used	 for	 microarray	 and	 sample	 processing	 (paraffin	 embedding)	 is	 incompatible	 with	
ganglioside	analysis	(Debarbieux	et	al.	2009;	Schwarz	&	Futerman	1997).	
4.5 GD3	 and	 GD3A	 turnover	 enzymes	 are	 atypically	 expressed	 in	
medulloblastoma	across	subgroups	and	metastatic	stages	
If	 the	expression	of	GD3	 is	considered	to	be	present,	 then	the	 two	major	enzymes	 that	
control	the	processing	of	GD3	to	GD3A	are	Cas1	and	SIAE.	The	expression	of	Cas1	was	found	
to	 be	 significantly	 up-regulated	 in	medulloblastoma	 tissue	 compared	 to	 non-neoplastic	
foetal	 and	 adult	 brain	 controls	 (p<0.0001)	 (figure	 3.2B).	 The	 high	 expression	 of	 Cas1	
suggests	 that	 there	 could	 be	 high	 expression	 of	 GD3A	 in	 these	 tumours.	 When	
medulloblastoma	tissue	samples	were	subgrouped,	the	expression	of	Cas1	was	shown	to	
be	 lowest	 in	WNT	and	SHH	subgroups	which	are	rarely	metastatic,	suggesting	they	may	
express	 less	 GD3A	 (figure	 3.6A).	 Cas1	 expression	 was	 significantly	 lower	 in	 the	 WNT	
subgroup	compared	to	group	3	(p<0.05;	figure	3.6A)	and	group	4	(p<0.001;	figure	3.6A)	this	
also	supports	the	hypothesis	that	the	least	metastatic	subgroup	expresses	less	GD3A	than	
the	more	metastatic	subgroups.	Expression	was	significantly	 lower	 in	 the	SHH	subgroup	










When	 expression	 of	 Cas1	was	 characterised	 by	metastatic	 stage,	 increasing	 expression	
correlated	with	increasing	M	stage	(figure	3.8A).	There	was	significantly	higher	expression	




Further	characterisation	of	 this	pathway	 involved	 the	human	endogenous	deacetylation	
enzyme	SIAE.	This	enzyme	was	an	important	discovery	to	the	regulation	of	this	pathway	
and	also	 its	use	as	a	therapeutic	target.	Previous	studies	 involving	deacetylation	of	GD3	
have	 utilised	 enzymes	 that	 are	 not	 endogenous,	 such	 as	 the	 influenza	 enzyme	
haemagluttinin	esterase	used	by	Birks	et.	al	for	a	study	on	glioblastoma	multiforme	(Birks	
et	 al.	 2011).	 This	 enzyme	proved	 to	be	highly	 immunogenic,	 since	 it	was	not	human	 in	
origin,	and	therefore	would	not	be	able	to	be	used	in	the	clinic.	This	study,	if	successful,	
could	 overcome	 this	 problem,	 as	 the	 human	 endogenous	 enzyme	 would	 not	 be	
immunogenic.		
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The	 expression	 of	 SIAE	 was	 significantly	 down-regulated	 in	 medulloblastoma	 tissue	
compared	to	non-neoplastic	foetal	and	adult	brain	controls	(p<0.0001)	(figure	3.2C).	This	





























This	 is	 only	 supported	 by	 bioinformatics	 data	 for	 Cas1,	 which	 shows	 an	 increase	 of	














36.0,	 17.5	 and	 0.6	%	 respectively,	whereas	 GD3	 expression	was	 55.0,	 62.2	 and	 77.1	%	
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a	group	4	medulloblastoma	(Erdreich-Epstein	et	al.	2014).	 It	 can	be	speculated	that	 the	
RES256	cell	line	belongs	to	either	the	SHH	or	WNT	subgroup	as	this	cell	line	harbours	a	TP53	
mutation	(Zhukova	Thesis,	2012).	TP53	mutations	are	enriched	in	WNT	patients	(16%)	and	
SHH	 patients	 (21%),	 and	 these	 mutations	 are	 virtually	 absent	 in	 group	 3	 and	 group	 4	
tumours	(p<0.001)	(Zhukova	et	al.	2013).	The	absence	of	TP53	mutations	in	groups	3	and	4	












2008),	 however	 the	 localisation	 of	 the	 gangliosides	 is	 very	 sensitive	 to	 fixation	method	
(Debarbieux	et	al.	2009;	Schwarz	&	Futerman	1997)	and	therefore	no	conclusions	will	be	














P60	 brain	 is	 in	 agreement	 with	 the	 literature	 stating	 that	 the	 expression	 of	 these	
gangliosides	 is	virtually	absent	 in	the	adult	brain	(Svennerholm	et	al.	1989).	 	 In	order	to	








ventricle	 and	often	 infiltrates	 the	brain	 stem	and	 the	 SHH	 subgroup	often	arises	 in	 the	
cerebellar	 hemispheres	 (World	 Health	 Organisation	 2007).	 From	 this	 study	 it	 was	 not	
possible	 to	 determine	 precise	 locations	 from	 the	 tissue	 available	 but	 would	 be	 an	






similar	 levels	 of	 GD3A	 in	 the	 three	 cell	 lines	 investigated,	 the	 cell	 line	with	 the	 highest	
percentage	of	intracellular	GD3A	expression,	RES256	was	chosen.	Many	attempts	at	stable	
cell	lines	using	pEGFP-N3,	pEGFP-N3-SIAE	and	pEGFP-N3-SIAE-His	constructs	were	carried	















An	 inducible	 system	 approach	 was	 used	 to	 over-express	 SIAE	 that	 allowed	 cells	 to	 be	
cultured	in	the	absence	of	expression	from	the	construct,	maintaining	viability.	In	order	to	
screen	the	initial	expression	of	the	construct	pCMV-TetOn3G,	a	Tet-responsive	luciferase	
assay	 was	 used	 and	 showed	 that	 this	 protein	 was	 capable	 of	 inducing	 expression	 of	
luciferase	and	therefore	was	suitable	 for	 induction	of	SIAE	expression	(appendix	4).	The	






































cloned	 into	 the	 plasmid	 (p<0.05;	 figure	 3.22A).	 When	 the	 expression	 of	 GD3	 was	
determined	it	was	shown	that	there	was	no	significant	increase	in	expression,	suggesting	
that	 GD3A	 deacetylation	 that	 did	 occur	 should	 not	 affect	 the	mitochondrial	membrane	
potential.		
In	the	catalytic	mutant	SIAE-S127A,	there	were	no	significant	changes	in	the	expression	of	




As	 high	 levels	 of	 GD3	 are	 known	 to	 collapse	 the	 mitochondrial	 membrane	 potential	
(Malisan	 &	 Testi	 2002a),	 this	 was	 explored	 (figure	 3.23).	 It	 is	 also	 known	 that	 these	
gangliosides	exist	in	balance	in	order	to	protect	cells	from	apoptosis	(Birks	et	al.	2011)	and	
therefore	the	collapse	of	the	mitochondrial	membrane	potential	would	only	occur	if	this	





































Another	 role	 of	 caspase	 1	 is	 within	 the	 inflammasome,	 it	 has	 been	 suggested	 in	
medulloblastoma	 that	 ATP	 is	 released	 by	 apoptotic	 cells	 and	 recruits	 the	 NLRP3	
inflammasome	(Knight	et	al.	2013)	via	the	purine	receptor	P2X7	the	mechanism	of	which	










the	 dose	 of	 existing	 treatments	 in	 order	 to	 reduce	 toxicity.	Our	 approach	 for	 this	 is	 to	
overexpress	SIAE	to	try	and	predispose	medulloblastoma	cells	to	existing	treatments.	The	




Following	 literature	 searches	 and	 searches	 of	 clinical	 trial	 data,	 cisplatin	 and	 etoposide	









DNA	 damage	 in	 cancer	 cells	 which	 block	 cell	 division	 and	 result	 in	 apoptosis.	 	 The	
intrastrand	cross-links	of	purine	bases	are	the	most	notable	changes	in	DNA	with	cisplatin	





cisplatin	 in	 wild-type	 SIAE	 clone	 1	 (p<0.001)	 but	 this	 effect	 was	 not	 concentration-
dependent	 and	was	 not	maintained	with	 higher	 doses	 (figure	 3.24B).	 There	was	 also	 a	
significant	reduction	in	cell	viability	of	S127A	expressing	cells	with	cisplatin	treatment	with	
4	and	11	μM	(p<0.05;	figure	3.24B)	and	with	12	μM	cisplatin	(p<0.01;	figure	3.24B).	After	
72	hours	of	 cisplatin	 treatment	 there	was	 a	 significant	difference	 in	 EGFP	 viability	with	
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vehicle	control	(p<0.05;	figure	3.24C)	and	7	μM	cisplatin	treatment	(p<0.05;	figure	3.24C).	












significant	depolarisation	of	 the	mitochondrial	membrane	potential,	 it	may	be	 that	 this	
effect	does	not	involve	the	gangliosides.		
As	 well	 as	 this,	 cells	 were	 still	 viable,	 even	 with	 high	 concentrations	 of	 cisplatin,	
mechanisms	 of	 resistance	 were	 investigated.	 (Siddik	 et	 al.	 2003)	 suggests	 many	
mechanisms	of	resistance;	two	of	these	are	relevant	to	the	RES256	cell	line.	TP53	mutation	
can	contribute	to	resistance	by	inhibition	of	p53-dependent	apoptotic	programs.	Another	
mechanism	 is	 overexpression	 of	 ERBB2	 (Her2)	 which	 is	 known	 to	 correlate	 with	 poor	
prognosis	in	medulloblastoma.		There	are	several	pathways	that	ERBB2	overexpression	can	
affect	which	 contribute	 to	 cisplatin	 resistance,	 but	 the	major	mechanism	 in	 this	 case	 is	





Etoposide	 is	 a	 chemotherapeutic	 whose	 main	 target	 is	 topoisomerase	 II,	 an	 enzyme	
involved	in	inducing	double	strand	transient	breaks	in	DNA	in	order	for	a	cell	to	replicate,	
and	for	 tangles	 in	DNA	to	be	removed.	The	transient	breaks	 in	DNA	are	generated	by	a	
topoisomerase	II	/	DNA	complex	(cleavage	complex)	which	can	be	stabilised	permanently	
by	etoposide.	This	drug	prevents	re-ligation	of	the	double-strand	DNA	break.	These	double-
strand	 DNA	 breaks	 are	 lethal	 to	 the	 cell	 as	 there	 is	 failure	 in	 DNA	 damage	 repair	
mechanisms	(Montecucco	et	al.	2015).	The	tumour	suppressor	p53	plays	an	important	role	
in	etoposide-induced	apoptosis	 and	 is	 regulated	by	 the	drug	 (Dey	et	 al.	 2010).	Another	
mechanism	of	action	of	etoposide	has	been	described	in	isolated	mitochondria	from	Jurkat	







μM	treatment	 (p<0.01;	 figure	3.25A).	 In	SIAE	wild-type	expressing	cells	 (clone	2)	12	μM	
etoposide	treatment	also	had	a	significant	difference	with	gene	expression	(p<0.01;	figure	






After	72	hours	of	 cisplatin	 treatment	 there	was	a	 significant	difference	1	μM	etoposide	
treated	cells	(p<0.05;	figure	3.25C).	
Clinically	achievable	levels	of	etoposide	in	the	brain	are	not	well	reported	in	the	literature.	
Publications	 on	 extraneural	 tumours	 such	 as	 neuroblastoma	 (Kiya	 et	 al.	 1992)	 and	
leukaemia	suggest	levels	in	the	plasma	can	reach	up	to	50	µM	(Wen	et	al.	2000)	this	is	very	






et	 al.	 2000).	 In	 addition,	 the	effects	of	 etoposide	 are	potentiated	with	 time	 (Kiya	 et	 al.	
1992).	 Despite	 early	 indications	 of	 etoposide	 seeming	 more	 effective	 using	 our	 initial	

















The	 reported	 IC50	data	obtained	 from	MTS	experiments	 shown	 in	 figures	3.26	and	3.27	
should	not	be	considered	final.	MTS	experiments	report	the	metabolic	state	of	cells	and	it	


















two	 gangliosides	 in	 medulloblastoma	 cell	 viability	 by	 over-expressing	 the	 human	
endogenous	deacetylation	enzyme	SIAE.	Over-expression	of	SIAE	significantly	increased	the	
expression	of	GD3	in	these	cells,	but	not	in	catalytic	mutant	cells	or	empty	vector	controls.	
Further	 to	this	we	demonstrated	 in	preliminary	work	that	 the	mitochondrial	membrane	
potential	could	be	depolarised	with	induction	of	SIAE	over-expression	(in	clone	1	only),	but	
experimental	limitations	make	conclusions	difficult	to	draw,	other	methods	such	as	caspase	




in	 susceptibility	 to	 cisplatin-mediated	 reductions	 in	 cell	 viability	 possibly	 in	 wild-type	








increase,	 something	 not	 desirable	 in	 a	 therapy.	 If,	 however	 trafficking	 of	 GD3	 to	 the	
mitochondria	 is	 sufficient	 to	 cause	 a	 reduction	 in	 cell	 viability	 this	 increase	 in	 invasive	
potential	would	be	unlikely.	 In	 support	of	 this,	 studies	on	 this	 pathway	 in	 glioblastoma	
multiforme	showed	that	invasive	potential	was	not	increased	upon	cleavage	of	GD3A	(Birks	
et	al.	2011).		
We	 also	 demonstrate	 that	 SIAE	 can	 be	 secreted	 and	 that	 there	 is	 a	 greater	 amount	 of	
secretion	in	the	catalytically	mutated	clone.	This	may	be	due	to	caspase	1	involvement,	but	
will	 be	 subject	 to	 further	work	 to	 support	 or	 reject	 this	 hypothesis	 and	 further	 dissect	
















these	 experiments	 to	 be	 carried	 out	 in	 further	 work.	 Other	 considerations	 should	 be	
combinations	 of	 chemotherapy	 to	 determine	 if	 any	 synergism	 occurs	 with	 SIAE	 over-
expression	 and	 current	 therapeutic	 regimes.	 Of	 particular	 interest	 would	 be	



















































































































































































































































































































































































































































































































































































































































































































































































































































































































The	 vector	 backbone	 also	 contains	 an	 SV40	 origin	 of	 replication	 in	 mammalian	 cells	
expressing	the	SV40	T-antigen.	A	neomycin	resistance	gene	(Neor)	consisting	of	the	SV40	






























The	 sequences	 contained	within	 pEGFP-N3	 and	pEGFP-SIAEHis	were	 homologous	 to	





Appendix	 2	 –	 Transfection	 efficiency	 and	 GD3/GD3A	 changes	 in	 cells	
transfected	with	pEGFP-N3,	pEGFP-N3-SIAE	and	pEGFP-N3-SIAEHis		
	













































































































Appendix	 2.2	 Transfection	 efficiency	 is	 low	 in	





Appendix	 3	 –	 Plasmid	 maps	 and	 sequence	 homology	 of	 pCMV-TetOn3G,	














(or	 SIAE-S127A).	 The	 PTRE3G	 promoter	 lacks	 binding	 sites	 for	 endogenous	 mammalian	
transcription	factors	so	is	virtually	silent	in	the	absence	of	doxycycline.		




























































































clones	 were	 tested	 to	 confirm	 expression	 of	 doxycycline-responsive	 protein.	



















































time.	 A	 doseof	 1000	µg/mL	 caused	 a	 signficant	 reduction	 in	
viability	after	5	days	(green)	and	by	15	days	(pink)	viability	had	












with	other	cell	 lines	and	microbes.	The	cell	 lines	used	 throughout	 this	project	were	 the	
medulloblastoma	 cell	 lines	 RES256,	 CHLA-01-Med	 and	UW402,	 and	 also	 the	metastatic	
melanoma	cell	line	MeWo.	
The	authenticity	of	cell	 lines	used	 in	the	following	experiments	were	confirmed	by	DNA	















































(B)	 RES256,	 (C)	 UW402	 and	 (D)	 CHLA-01-Med	 medulloblastoma	 cell	 lines.	 These	




















































adherent	 medulloblastoma	 cell	 line	 Passage	 106;	 (D)	 CHLA-01-Med	 a	 group	 4	







The	 IC50	 is	 the	 concentration	 of	 (inhibitory)	 drug	 (or	 antagonist)	 required	 for	 a	 50	 %	
reduction	in	response.	In	this	case	the	concentration	of	chemotherapeutic	required	for	a	





































EGFP	 Cisplatin	 4.3 ± 1.2 4.2 ± 0.9 24	 0.9303 No	
SIAE	1	 Cisplatin	 3.7 ± 1.4 n.d 24	 0.4091 No	
SIAE	2	 Cisplatin	 3.4 ± 1.3 2.4 ± 1.1 24	 0.4091 No	
S127A	 Cisplatin	 3.1 ± 1.3 2.7 ± 0.8 24	 0.6675 No	
EGFP	 Etoposide	 4.6 ± 3.8 n.d 24	 0.8028 No 
SIAE	1	 Etoposide	 2.4 ± 1.1 3.0 ± 2.2 24	 0.7065 No	
SIAE	2	 Etoposide	 4.1 ± 1.9 1.2 ± 0.9 24	 0.0744 No	
S127A	 Etoposide	 n.d 4.5 ± 2.0 24	 0.1691 No	
EGFP	 Cisplatin	 3.6 ± 2.9 3.8 ± 1.2 48	 0.8485 No	
SIAE	1	 Cisplatin	 2.3 ± 0.4 2.0 ± 0.4 48	 0.2769 No	
SIAE	2	 Cisplatin	 1.8 ± 0.7 2.8 ± 0.5 48	 0.1058 No	
S127A	 Cisplatin	 4.1 ± 0.6 3.1 ± 0.5 48	 0.0165 Yes	
EGFP	 Etoposide	 6.7 ± 2.9 6.6 ± 1.8 48	 0.9785 No	
SIAE	1	 Etoposide	 3.0 ± 0.6 2.3 ± 0.6 48	 0.1547 No	
SIAE	2	 Etoposide	 2.1 ± 0.5 1.6 ± 0.5 48	 0.3322 No	
S127A	 Etoposide	 3.0 ± 0.6 2.8 ± 0.5 48	 0.6991 No	
EGFP	 Cisplatin	 2.7 ± 0.6 2.0 ± 0.6 72	 0.1727 No	
SIAE	1	 Cisplatin	 1.3 ± 0.3 1.0 ± 0.2 72	 0.2153 No	
SIAE	2	 Cisplatin	 1.1 ± 0.3 1.1 ± 0.3 72	 0.9892 No	
S127A	 Cisplatin	 1.8 ± 0.4 1.7 ± 0.4 72	 0.7893 No	
EGFP	 Etoposide	 3.0 ± 1.4 4.2 ± 1.1 72	 0.3198 No	
SIAE	1	 Etoposide	 3.5 ± 0.3 2.8 ± 0.2 72	 0.3899 No	
SIAE	2	 Etoposide	 5.1 ± 1.3 1.9 ± 0.9 72	 0.0034 Yes	








Appendix	 8.1	 NG2	 mRNA	 expression	 in	 Medulloblastoma	 subgroups.	 NG2	 expression	 is	
highest	 in	 WNT	 group	 of	 Medulloblastomas	 providing	 supportive	 evidence	 that	 GD3A	
expression	is	lowest	in	this	subgroup	as	also	supported	by	data	in	chapter	3	and	published	
work	 which	 demonstrates	 an	 inverse	 correlation	 between	 NG2	 and	 GD3A	 expression	 in	
glioma.	Similar	expression	of	NG2	is	seen	in	SHH	group	3	and	group	4	samples.	(Data	from	
Taylor	group,	Toronto).		
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Appendix	9	–	UPR16	Form	and	ethical	approval	letter	
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